EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS

Abstract

Compositions comprising a therapeutically effective amount of a multikinase inhibitor, such as nintedanib, axitinib, or pazopanib, are provided, wherein the composition is an emulsion, such as a nanoemulsion, with a lipophilic vehicle (e.g., castor oil), a polyoxyl oil (e.g., polyolyl-35 castor oil), optionally with a surfactant (e.g., polysorbate 80), and optionally with a cyclic oligosaccharide, such as a cyclodextrin (e.g., 2-hydroxypropyl-beta-cyclodextrin), as a solubilizer. Methods for treating eye conditions with the compositions are also provided.

Description

EMULSION FORMULATIONS OF MULTIKINASE INHIBITORS REFERENCE TO RELATED PATENT APPLICATION This application claims the benefit of the United States provisional application N.ede Series 62 / 723.998, filed on August 28, 2018, the contents of which are incorporated herein by reference in their entirety. TECHNICAL FIELD This document provides formulations for the administration of multikinase inhibitors. BACKGROUND Multikinase inhibitors are inhibitors that target more than one protein kinase. Protein kinases are enzymes that add a phosphate group to a protein and can modulate its function. Phosphorylation regulates many biological processes, and multikinase inhibitors can be used to treat various diseases or to modulate cellular functions. The therapeutic potential of such compounds depends, at least in part, on how well they can be formulated and delivered for specific treatments. BRIEF DESCRIPTION OF THE INVENTION This document provides formulations for the administration of multikinase inhibitors. In some embodiments, formulations and methods are provided for treating one or more eye conditions. The disclosure provides compositions for treating eye conditions, including diseases affecting the anterior segment of the eyes. The composition may comprise a therapeutically effective amount of a multikinase inhibitor, such as nintedanib, axitinib, or pazopanib, wherein the composition is an emulsion, such as a nanoemulsion (e.g., comprising castor oil, polyoxyl-35 castor oil, and optionally polysorbate 80), with a cyclic oligosaccharide, such as a cyclodextrin (e.g., 2-hydroxypropyl-betacyclodextrin), as a solubilizer, and is suitable for topical administration to the eyes. The disclosure further provides methods for treating eye conditions with the disclosed compositions. In some embodiments, a composition suitable for topical administration to an eye is provided comprising a therapeutically effective amount of a multikinase inhibitor, such as nintedanib or axitinib or pazopanib, wherein said composition comprises an emulsion, such as a nanoemulsion, with cyclodextrin, such as 2-h hydroxypropylbeta-cyclodextrin, as a solubilizer.In some embodiments, methods are provided for treating an ocular condition associated with angiogenesis, such as hyperemia, neovascularization, pterygium, pinguecula, glaucoma filtration surgery and minimally invasive glaucoma surgery (MIGS), corneal transplant surgery with graft rejection, graft-versus-host disease, dry eye disease, atopic conjunctivitis, rosacea, ocular pemphigoid, Lyell's syndrome, Stevens-Johnson syndrome, viral infection (e.g., HSV-1), bacterial infection, fungal infection, parasitic infection, contact lens-induced neovascularization, ulceration, alkali burns, and stem cell deficiency. In one aspect, an emulsion is provided, including a therapeutically effective amount of a multikinase inhibitor; a solubilizer; a lipophilic vehicle; and one or more surfactants. In one aspect, an emulsion is provided, including a therapeutically effective amount of a multikinase inhibitor; polyoxyl oil; a solubilizer; a lipophilic vehicle; and one or more surfactants. This and other embodiments may also optionally include one or more of the following features. In some embodiments, the emulsion may be a nanoemulsion. In some embodiments, the multikinase inhibitor may be selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations thereof. In some embodiments, the solubilizer may be a cyclic polysaccharide. In some embodiments, the cyclic polysaccharide may be selected from cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-betacyclodextrin, and combinations thereof. In some embodiments, the lipophilic vehicle may be selected from castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof. In some embodiments, the surfactant may be selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, polyoxyl-35 castor oil, polyoxyl-40 castor oil, tocopherol, and other polymeric emulsifiers and combinations thereof. In some embodiments, the multikinase inhibitor is nintedanib, the solubilizer is 2-hydroxypropyl-beta-cyclodextrin, the lipophilic vehicle is castor oil, and the surfactant is polysorbate 80, polyoxyl-35 castor oil, or a combination thereof. In some embodiments, the multikinase inhibitor may be present in an amount of approximately 0.001% w / w to approximately 10.0% w / w. In some embodiments, the multikinase inhibitor is nintedanib, and nintedanib may be present in an amount of approximately 0.01% w / w to approximately 10.0% w / w. In some embodiments, the multikinase inhibitor is axitinib, and axitinib may be present in the emulsion in an amount of approximately 0.001% w / w to approximately 1.0% w / w. In some embodiments, the multikinase inhibitor is axitinib, and axitinib may be present in the emulsion in an amount of approximately 0.001% w / w to approximately 10.0% w / w. In some embodiments, the multikinase inhibitor is pazopanib and pazopanib may be present in an amount of approximately 0.01% w / w to approximately 10.0% w / w.In some embodiments, the lipophilic vehicle may be present in an amount of approximately 0.01% w / w or approximately 5.0% w / w. In some embodiments, the surfactant may be present in an amount of approximately 0.01% w / w to approximately 10% w / w. In some embodiments, the solubilizer may be present in the emulsion in an amount of approximately 1% w / w to approximately 20% w / w. In some embodiments, the emulsion may further comprise an additional constituent selected from the group consisting of a thickener, a buffering agent, a tonicity agent, an antioxidant, a preservative, and combinations thereof. In some embodiments, the thickener may be selected from the group consisting of carbomer, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, xanthan gum, and combinations thereof. In some embodiments, the thickener may be hydroxypropyl methylcellulose or sodium carboxymethylcellulose and the thickener is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. In some embodiments, the buffering agent may be selected from the group consisting of phosphates, citrates, acetates, borates, and combinations thereof.In some embodiments, the buffering agent may be selected from the group consisting of monobasic sodium phosphate monohydrate, monosodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, and boric acid, and the buffering agent is present in the emulsion in a sufficient amount to maintain the pH in the range of 4.0 to 8.0. In some embodiments, the antioxidant may be selected from the group consisting of disodium edetate, dibutylhydroxytoluene, citric acid, sodium metabisulfite, tocopheryl acetate, and combinations thereof. In some embodiments, the antioxidant may be disodium edetate, and the antioxidant is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. In some embodiments, the tonicity agent may be selected from the group consisting of sodium chloride, glycerin, mannitol, potassium chloride, erythritol, and combinations thereof.In some embodiments, the tonic agent may be glycerin, and the tonic agent is present in an amount of approximately 0.1% w / w to approximately 10% w / w. In some embodiments, the tonic agent may be present in a sufficient amount to maintain the osmolarity in the range of 250 to 400 mOsm / kg. In some embodiments, the emulsion may be preservative-free. In some embodiments, the emulsion may further comprise a preservative selected from a group consisting of BAK, PHMB, Purite®, sorbic acid, and combinations thereof. In some embodiments, the emulsion may have an average droplet size of approximately 10 nm to 100,000 nm. In some embodiments, the emulsion may have an average droplet size of 200 nm or less. In some embodiments, the emulsion may have an average droplet size of 100 nm or less. In some embodiments, the emulsion may have an average droplet size of 75 nm or less. In some embodiments, the emulsion may have an average droplet size of approximately 25 to approximately 200 nm (e.g., approximately 25 to approximately 150 nm, approximately 25 to approximately 100 nm, approximately 25 to approximately 75 nm, approximately 50 to approximately 200 nm, approximately 50 to approximately 150 nm, or approximately 50 to approximately 100 nm).Without wishing to be bound to any particular theory, it is believed that, at least for some emulsions (e.g., those described herein), a smaller droplet size may lead to a longer phase separation time and / or a longer emulsion stability time. Similarly, without wishing to be bound to any particular theory, it is believed that, at least for some emulsions (e.g., those described herein), a smaller droplet size may increase the emulsion's transparency; for example, an emulsion with a small droplet size (e.g., approximately 50 nm) may be almost transparent, whereas a larger droplet size, or an emulsion that has separated, may have a milky appearance. In some embodiments, the emulsion may remain stable for at least 6 months at 25°C. In some embodiments, the emulsion may remain stable for at least 12 months at 25°C. In some embodiments, the emulsion may remain stable for at least 24 months at 25°C. In some embodiments, the emulsion may remain stable for at least 1 month at 40°C. In some embodiments, the emulsion may remain stable for at least 2 months at 40°C. In some embodiments, the emulsion may be formulated as an eye drop, cream, gel, ointment, film, or sustained-release implant. In another aspect, a method is provided for prolonging the residence time of a multikinase inhibitor on the ocular surface, comprising administering any one or more of the emulsions described herein to a subject's eye. In some embodiments, administration may comprise applying the emulsion to the eye at least once daily. In some embodiments, administration may comprise applying the emulsion to the eye at least twice daily. In some embodiments, administration may comprise applying the emulsion to the eye at least three times daily. In another aspect, a method is provided for treating an ocular condition, comprising administering any one or more of the emulsions described herein to a subject's eye. In some embodiments, the ocular condition may be associated with angiogenesis. In some embodiments, the ocular condition may be selected from hyperemia, neovascularization, pterygium, pinguecula, glaucoma filtration surgery and minimally invasive glaucoma surgery (MIGS), corneal transplant surgery with graft rejection, graft-versus-host disease, dry eye disease, atopic conjunctivitis, rosacea, ocular pemphigoid, Lyell's syndrome, Stevens-Johnson syndrome, viral infection (e.g., HSV-1), bacterial infection, fungal infection, parasitic infection, contact lens-induced neovascularization, ulceration, alkali burns, and stem cell deficiency. In another aspect, the present document provides an emulsion comprising nrzznn / Lznz / E / YiAi a therapeutically effective amount of a multikinase inhibitor, a polyoxyl oil, a lipophilic vehicle, and water. Implementations may include one or more of the following features. The emulsion may be a nanoemulsion. The multikinase inhibitor may be selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib, or combinations thereof. The multikinase inhibitor may be selected from axitinib, nintedanib, and pazopanib. The multikinase inhibitor may be axitinib. The multikinase inhibitor may be nintedanib. The multikinase inhibitor may be pazopanib. The emulsion may also include a solubilizer.The solubilizer may be a cyclic polysaccharide. The cyclic polysaccharide may be selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, and combinations thereof. The polyoxyl oil may be polyoxyl castor oil. The polyoxyl castor oil may be polyoxyl castor oil 40, polyoxyl castor oil 35, or a combination thereof. The lipophilic vehicle may be selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof.The emulsion may further include a surfactant selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol, and combinations thereof. The multikinase inhibitor may be nintedanib, the solubilizer may be 2-hydroxypropyl-beta-cyclodextrin, the lipophilic vehicle may be castor oil, and the polyoxyl oil may be polyoxyl-35 castor oil or a combination thereof. The multikinase inhibitor may be present in an amount of approximately 0.001% w / w to approximately 10.0% w / w. The multikinase inhibitor may be present in an amount of approximately 0.01% to approximately 1% w / w. The multikinase inhibitor may be present in an amount of approximately 0.1% to approximately 0.5% w / w.The multiple kinase inhibitor may be nintedanib, and nintedanib may be present in the emulsion in an amount of approximately 0.01% w / w to approximately 10.0% w / w. The multikinase inhibitor may be axitinib, and axitinib may be present in the emulsion in an amount of approximately 0.001% w / w to approximately 10.0% w / w. Axitinib may be present in an amount of approximately 0.05% to approximately 0.5% w / w.The multikinase inhibitor may be pazopanib, and pazopanib may be present in an amount of approximately 0.01% w / w to approximately 10.0% w / w. Pazopanib may be present in an amount of approximately 0.01% to approximately 1% w / w. Pazopanib may be present in an amount of approximately 0.1% to approximately 0.5% w / w. The lipophilic vehicle may be present in an amount of approximately 0.01% w / w to approximately 5.0% w / w. The lipophilic vehicle may be present in an amount of approximately 0.05% to approximately 1% w / w. The lipophilic vehicle may be present in an amount of approximately 0.1% to approximately 0.5% w / w. Polyoxyl oil may be present in an amount of approximately 0.01% w / w to approximately 10% w / w. Polyoxyl oil may be present in an amount of approximately 0.05% to approximately 1% w / w.Polyoxyl oil may be present in an amount of approximately 0.1% to approximately 0.5% w / w. The emulsion may further include a solubilizer, wherein the solubilizer may be present in the emulsion in an amount of approximately 1% w / w to approximately 20% w / w. The solubilizer may be present in an amount of approximately 5% to approximately 15% w / w. The solubilizer may be present in an amount of approximately 8% to approximately 12% w / w. The emulsion may further include an additional constituent selected from the group consisting of a thickener, a buffering agent, a tonicity agent, an antioxidant, and combinations thereof. The thickener may be selected from the group consisting of carbomer, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, xanthan gum, and combinations thereof.The thickener may be hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or a combination thereof. The thickener may be present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. The thickener may be present in an amount of approximately 0.05% w / w to approximately 0.5% w / w. The buffering agent may be selected from the group consisting of phosphates, citrates, acetates, borates, and combinations thereof. The buffering agent may be selected from the group consisting of sodium citrate dihydrate, sodium citrate, monobasic sodium phosphate monohydrate, monosodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, boric acid, and combinations thereof. The buffering agent may be selected from the group consisting of sodium citrate dihydrate, sodium citrate, or a combination thereof.The buffering agent may be present in the emulsion in a sufficient amount to maintain the pH in the range of 4.0 to 8.0. The buffering agent may be present in the emulsion in a sufficient amount to maintain the pH in the range of approximately 5.5 to approximately 6.5. The buffering agent may be present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. The buffering agent may be present in an amount of approximately 0.03% w / w to approximately 0.06% w / w. The antioxidant may be selected from the group consisting of disodium edetate, dibutylhydroxytoluene, citric acid, sodium metabisulfite, tocopheryl acetate, and combinations thereof. The antioxidant may be selected from the group consisting of disodium edetate, citric acid, and combinations thereof. The antioxidant may be present in an amount of approximately 0.01% to approximately 1.0% w / w.The antioxidant may be present in an amount of approximately 0.05% to approximately 0.5% w / w. The antioxidant may include disodium edetate, and disodium edetate may be present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. The antioxidant may include disodium edetate, and disodium edetate may be present in an amount of approximately 0.05% w / w to approximately 0.5% w / w. The antioxidant may include citric acid, and citric acid may be present in an amount of approximately 0.001% to approximately 0.1% w / w. The antioxidant may include citric acid, and citric acid may be present in an amount of approximately 0.005% to approximately 0.05% w / w. The tonicity agent may be selected from the group consisting of sodium chloride, glycerin, mannitol, potassium chloride, erythritol, and combinations thereof. The toning agent can be glycerin.The tonicity agent may be present in an amount of approximately 0.1% w / w to approximately 10% w / w. The tonicity agent may be present in an amount of approximately 0.01% w / w to approximately 1% w / w. The tonicity agent may be present in an amount of approximately 0.05% w / w to approximately 0.5% w / w. The tonicity agent may be present in an amount sufficient to maintain the osmolarity in the range of 250 to 400 mOsm / kg. The emulsion may further include a preservative. The preservative may be selected from the group consisting of benzalkonium chloride (BAK), polyhexamethylene biguanide (PHMB), a stabilized oxychlor complex, sorbic acid, and combinations thereof. The emulsion may be preservative-free. The emulsion has an average droplet size of between approximately 10 nm and 100,000 nm.The emulsion has an average droplet size of 200 nm or less. The emulsion can remain stable for at least 6 months at 25°C. The emulsion can remain stable for at least 12 months at 25°C. The emulsion can remain stable for at least 24 months at 25°C. The emulsion can remain stable for at least 6 months at 40°C. The emulsion can remain stable for at least 12 months at 40°C. The emulsion can remain stable for at least 24 months at 40°C. The emulsion can remain stable for at least 6 months at 50°C. The emulsion can remain stable for at least 12 months at 50°C. The emulsion can remain stable for at least 24 months at 50°C. The emulsion can remain stable for at least 6 months at 60°C. The emulsion can remain stable for at least 12 months at 60°C. The emulsion can remain stable for at least 24 months at 60°C.The emulsion can be formulated as an eye drop, a cream, a gel and ointment, a film. In another aspect, the present document provides an emulsion comprising approximately 0.05% to approximately 1% w / w of a multikinase inhibitor, approximately 0.1% to approximately 1% w / w of a polyoxyl oil, approximately 0.05% to approximately 1% w / w of a lipophilic vehicle, approximately 5% to 15% w / w of a solubilizer, and water. In another aspect, the present document provides an emulsion comprising approximately 0.005% to approximately 2% w / w of a multikinase inhibitor, approximately 0.1% to approximately 1% w / w of a polyoxyl oil, approximately 0.05% to approximately 1% w / w of a lipophilic vehicle, approximately 5% to 15% w / w of a solubilizer, and water. Implementations may include one or more of the following features. The multikinase inhibitor may be present in an amount of approximately 0.1% to approximately 0.5% w / w. The polyoxyl oil may be present in an amount of approximately 0.3% to approximately 0.7% w / w. The lipophilic vehicle may be present in an amount of approximately 0.1% to approximately 0.5% w / w. The solubilizer may be present in an amount of approximately 8% to approximately 12% w / w. In another respect, the present document provides an emulsion comprising approximately 0.1% to approximately 0.5% w / w of a multikinase inhibitor, approximately 0.3% to approximately 0.7% w / w of a polyoxyl oil, approximately 0.1% to approximately 0.5% w / w of a lipophilic vehicle, approximately 8% to 12% w / w of a solubilizer, and water. The emulsion formulations provided herein may include one or more of the following features. The multikinase inhibitor may be present in an amount of approximately 0.2% w / w. The polyoxyl oil may be present in an amount of approximately 0.5% w / w. The lipophilic vehicle may be present in an amount of approximately 0.25% w / w. The solubilizer may be present in an amount of approximately 10% w / w. In another respect, the present document provides an emulsion comprising approximately 0.2% w / w of a multikinase inhibitor, approximately 0.5% w / w of a polyoxyl oil, approximately 0.25% w / w of a lipophilic vehicle, approximately 10% w / w of a solubilizer, and water. The implementations of the emulsions provided in this document may include one or more of the following features. The multikinase inhibitor may be selected from the group consisting of afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations thereof. The multikinase inhibitor can be selected from axitinib, nintedanib, and pazopanib. The multikinase inhibitor can be axitinib. The multikinase inhibitor can be nintedanib. The multikinase inhibitor can be pazopanib. The solubilizer can be a cyclic polysaccharide.The cyclic polysaccharide may be selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alphacyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, and combinations thereof. The solubilizer may include (or be) 2-hydroxypropyl-beta-cyclodextrin. The polyoxyl oil may be polyoxyl castor oil. The polyoxyl castor oil may be polyoxyl-40 castor oil, polyoxyl-35 castor oil, or a combination thereof.The lipophilic vehicle may be selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof. The lipophilic vehicle may include (or be) castor oil. The emulsion may further include a surfactant. In some embodiments, the surfactant may be selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol, and combinations thereof. The surfactant may be present in an amount of approximately 0.05% to approximately 5% w / w. The surfactant may be present in an amount of approximately 0.1% to approximately 1% w / w.The inhibitor may be present in an amount of 0.5% w / w. The emulsion may further include an additional constituent selected from the group consisting of a thickener, a buffer, a tonicity agent, an antioxidant, and combinations thereof. The thickener may include hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or a combination thereof. The thickener may be present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. The thickener may be present in an amount of approximately 0.05% w / w to approximately 0.5% w / w. The thickener may be present in an amount of approximately 0.1% w / w. The buffer may include (or be) sodium citrate. The buffer may be present in the emulsion in an amount sufficient to maintain the pH in the range of approximately 5.5 to approximately 6.5.The buffering agent may be present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. The buffering agent may be present in an amount of approximately 0.03% w / w to approximately 0.06% w / w. The buffering agent may be present in an amount of approximately 0.045% w / w. The antioxidant may include disodium edetate, citric acid, or a combination thereof. The antioxidant may include disodium edetate, and disodium edetate may be present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. The antioxidant may include disodium edetate, and disodium edetate may be present in an amount of approximately 0.05% w / w. The antioxidant may include disodium edetate and the disodium edetate may be present in an amount of approximately 0.1% w / w.The antioxidant may include citric acid, and citric acid may be present in an amount of approximately 0.001% to approximately 0.1% w / w. The antioxidant may include citric acid, and citric acid may be present in an amount of approximately 0.005% to approximately 0.05% w / w. The antioxidant may include citric acid, and citric acid may be present in an amount of approximately 0.015%. The tonic agent may include (or may be) glycerin. The tonic agent may be present in an amount of approximately 0.01% w / w to approximately 1% w / w. The tonic agent may be present in an amount of approximately 0.05% w / w to approximately 0.5% w / w. The tonic agent may be present in an amount of approximately 0.1% w / w. In another aspect, the present document provides an emulsion comprising approximately 0.2% w / w of a multikinase inhibitor selected from the group consisting of nintedanib, axitinib and pazopanib, approximately 0.5% w / w of a polyoxyl castor oil, approximately 0.25% w / w of castor oil, approximately 10% w / w of 2-hydroxypropyl-beta-cyclodextrin and water. Implementations may include one or more of the following features. The multikinase inhibitor may be axitinib. The multikinase inhibitor may be nintedanib. The multikinase inhibitor may be pazopanib. The polyoxyl castor oil may be polyoxyl-40 castor oil, polyoxyl-35 castor oil, or a combination thereof. The emulsion may further include polysorbate 80 in an amount of approximately 0.5% w / w. The emulsion may further include hydroxypropyl methylcellulose in an amount of approximately 0.1% w / w. The emulsion may further include sodium citrate in an amount of approximately 0.045% w / w. The emulsion may further include disodium edetate in an amount of approximately 0.1% w / w. The emulsion may further include citric acid in an amount of approximately 0.015%. The emulsion may also include glycerin in an amount of approximately 0.1% w / w. In another respect, this document provides a method for prolonging the residence time of a multikinase inhibitor on the ocular surface, including the administration of any one or more of the emulsions provided herein. nrzznn / Lznz / E / YiAi Implementations may include one or more of the following features. Administration may include applying the emulsion to the eye at least once a day. Administration may include applying the emulsion to the eye at least twice a day. Administration may include applying the emulsion to the eye at least three times a day. Administration may include applying the emulsion to the eye once a day. Administration may include applying the emulsion to the eye twice a day. Administration may include applying the emulsion to the eye three times a day. In another aspect, this document provides a method for treating an eye condition, including the administration of any one or more of the emulsions provided herein to the eye of a subject. The eye condition may be associated with angiogenesis. Implementations may include one or more of the following features. The ocular condition may be selected from the group consisting of hyperemia, neovascularization, pterygium, pinguecula, glaucoma filtration surgery and minimally invasive glaucoma surgery (MIGS), corneal transplant surgery with graft rejection, graft-versus-host disease, dry eye disease, atopic conjunctivitis, rosacea, ocular pemphigoid, Lyell's syndrome, Stevens-Johnson syndrome, viral infection (e.g., HSV-1), bacterial infection, fungal infection, parasitic infection, contact lens-induced neovascularization, ulceration, alkali burns, and stem cell deficiency. The emulsion may remain stable for at least 1 month at 40°C. The emulsion may remain stable for at least 6 months at 40°C. The emulsion may remain stable for at least 12 months at 40°C.The emulsion may remain stable for at least 24 months at 40°C. Administration may include applying the emulsion to the eye at least once a day. Administration may include applying the emulsion to the eye at least twice a day. Administration may include applying the emulsion to the eye at least three times a day. Administration may include applying the emulsion to the eye once a day. Administration may include applying the emulsion to the eye twice a day. Administration may include applying the emulsion to the eye three times a day. In another aspect, the present document provides a method for preparing any of the emulsions described herein, including the method of forming a primary emulsion, reducing the droplet size of the primary emulsion to form a nanoemulsion, dissolving a multikinase inhibitor in a solution, combining the nanoemulsion and the solution to form a nanoemulsion including the multikinase inhibitor; and, optionally, filtering the nanoemulsion including the multikinase inhibitor. In another aspect, the present document provides a method for preparing an emulsion, including the method of forming a primary emulsion, reducing the droplet size of the primary emulsion to form a nanoemulsion, dissolving a multikinase inhibitor in a solution, combining the nanoemulsion and the solution to form a nanoemulsion including the multikinase inhibitor, and optionally filtering the nanoemulsion including the multikinase inhibitor. The implementation of the methods may include one or more of the following features. Primary emulsion formation may involve high-shear mixing. Droplet size reduction may involve the use of a microfluidizer. Filtration may involve the use of a 0.2-micrometer filter. The method may further involve loading the filtered nanoemulsion into sterile dropper bottles. The sterile dropper bottles are preservative-free multidose containers (MDSCs) or low-density polyethylene (LDPE) single-dose containers. The primary emulsion may include a polyoxyl oil, a lipophilic vehicle, and water.The multikinase inhibitor can be selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, cñzotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations thereof. The multikinase inhibitor may be selected from axitinib, nintedanib, and pazopanib. The multikinase inhibitor may be axitinib. The multikinase inhibitor may be nintedanib. The multikinase inhibitor may be pazopanib. The solution may also include a solubilizer. The solubilizer may be a cyclic polysaccharide.The cyclic polysaccharide may be selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, and combinations thereof. The polyoxyl oil may be polyoxyl castor oil. The polyoxyl castor oil may be polyoxyl castor oil 40, polyoxyl castor oil 35, or a combination thereof. The lipophilic vehicle may be selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof.The primary emulsion may also include a surfactant selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol, and combinations thereof. The multikinase inhibitor may be nintedanib, the solubilizer may be 2-hydroxypropyl-beta-cyclodextrin, the lipophilic vehicle may be castor oil, and the polyoxyl oil may be polyoxyl-35 castor oil or a combination thereof. The multikinase inhibitor may be present in the primary emulsion in an amount of approximately 0.001% w / w to approximately 10.0% w / w. The multikinase inhibitor may be present in the primary emulsion in an amount of approximately 0.1% to approximately 0.5% w / w.The lipophilic vehicle may be present in the primary emulsion in an amount of approximately 0.01% w / w to approximately 5.0% w / w. The lipophilic vehicle may be present in the primary emulsion in an amount of approximately 0.05% to approximately 1% w / w. The lipophilic vehicle may be present in the primary emulsion in an amount of approximately 0.1% to approximately 0.5% w / w. Polyoxyl oil may be present in the primary emulsion in an amount of approximately 0.01% w / w to approximately 10% w / w. Polyoxyl oil may be present in the primary emulsion in an amount of approximately 0.05% to approximately 1% w / w. Polyoxyl oil may be present in the primary emulsion in an amount of approximately 0.1% to approximately 0.5% w / w.The primary emulsion may further include a solubilizer, wherein the solubilizer may be present in the primary emulsion in an amount of approximately 1% w / w to approximately 20% w / w. The solubilizer may be present in the primary emulsion in an amount of approximately 5% to approximately 15% w / w. The solubilizer may be present in the primary emulsion in an amount of approximately 8% to approximately 12% w / w. The primary emulsion may further include an additional constituent selected from the group consisting of a thickener, a buffering agent, a tonicity agent, an antioxidant, and combinations thereof. The emulsion may be any of the emulsions described herein. Details of one or more embodiments of the invention are indicated in the accompanying drawings nrzznn / Lznz / E / YiAi and the description presented below. Other features, objects, and advantages of the invention will be apparent from the description and the drawings, as well as from the claims. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an example diagram of the concept of an example dual synergistic emulsion and solubilizing system used in some embodiments of the compositions described herein. Figure 2 is a graph showing the reduction of CNV in rabbit in an emulsion or solution of 0.2% nintedanib according to Example 6. DETAILED DESCRIPTION The description herein sets forth details to provide an understanding of various embodiments of the invention and is made with the understanding that the disclosures provided are an illustration of the claimed subject matter and are not intended to limit the claims to specific embodiments. Accordingly, the specific embodiments disclosed herein may be combined with other specific embodiments disclosed herein, including specific embodiments under various headings, which are provided for convenience and organization, but in no event shall they be construed as limiting the claims in any way. All published documents cited in this document are incorporated in their entirety for reference purposes. As used herein, the singular forms un, una, el / la are also intended to include the plural forms, unless the context clearly indicates otherwise. As used herein, and unless otherwise indicated, the term "approximately," when used in connection with a numerical value or range of values, is meant to describe that the value or range of values ​​may deviate to a degree considered reasonable to a person skilled in the art (for example, a specific temperature or range of temperatures). For example, the term "approximately," when used in this context, may, in some embodiments, indicate that the numerical value or range of values ​​may vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of the stated value or range of values. In some embodiments, the numerical value or range of values ​​may vary by 5%. Nintedanib, axitinib, and pazopanib are three potent multikinase inhibitors targeting the vascular endothelial growth factor receptor (VEGFR), the platelet-derived growth factor receptor (PDGFR), and / or the fibroblast growth factor receptor (FGFR). When formulated as an oral capsule or tablet, nintedanib, axitinib, and pazopanib are effective drug therapies for treating various types of cancer. However, nintedanib, axitinib, and pazopanib are insoluble in water, with a solubility at room temperature of less than 0.001 mg / mL. These physical and chemical properties may limit their application and may prevent effective delivery at therapeutically effective concentrations via topical ocular administration to target ocular tissues.Surprisingly, a synergistic effect of an emulsion system, optionally combined with a solubilizer such as a cyclic oligosaccharide (e.g., 2-hydroxypropyl-beta-cyclodextrin), has been found to enable the successful formulation of multikinase inhibitors, such as nintedanib, axitinib, or pazopanib, at a therapeutically effective concentration with sufficient stability to achieve a desirable shelf life. For example, the emulsion, and optionally the solubilizer, has unexpectedly been found to have a greater-than-additive effect on the solubility of multikinase inhibitors such as nintedanib, axitinib, or pazopanib. As shown in Figure 1, a multikinase inhibitor such as nintedanib, axitinib, or pazopanib can dissolve in this cyclic oligosaccharide system by becoming effectively trapped in the central cavity of a cyclic oligosaccharide.Although it is a cyclic oligosaccharide, such as 2-hydroxypropyl-beta-cyclodextrin, it can only dissolve a multikinase inhibitor, such as nintedanib, axitinib, or pazopanib, to a desired concentration, the cyclic oligosaccharide-multikinase inhibitor complex can still dissociate and cause precipitation of the multikinase inhibitor during long-term storage. Furthermore, and surprisingly, the emulsion systems described herein have been shown to be dosed less frequently (e.g., twice daily) while demonstrating similar or superior efficacy and / or pharmacokinetic properties (e.g., in multiple tissues) compared to, for example, a solution formulation (dosed, for example, three times daily or more). To further enhance stability, in some embodiments, a multikinase inhibitor, such as nintedanib, axitinib, or pazopanib, can form a complex with a lipophilic vehicle system, such as a lipophilic castor oil vehicle, and one or more surfactants, such as polysorbate 80 and polyoxyl-35 castor oil. The multikinase inhibitor would effectively dissolve at the interface of the oil droplets of the nezznn / Lznz / E / YiAi lipophilic vehicle system to form a stable formulation. In some embodiments, the solubility and stability of the multikinase inhibitor formulation can be further enhanced when the oil droplet size is less than or equal to approximately 200 nm.However, the surfactant concentrations in a lipophilic vehicle system alone, such as castor oil with a surfactant like polysorbate 80 and / or polyoxyl-35 castor oil, required to dissolve nintedanib, axitinib, or pazopanib to a concentration desired for topical ocular administration, can cause eye irritation in humans. Using an emulsion or nanoemulsion of castor oil, polysorbate 80, or polyoxyl-35 castor oil at low concentrations, optionally in combination with a cyclic oligosaccharide, creates a synergistic effect and can improve the overall solubility of nintedanib, axitinib, or pazopanib to achieve the desired solubility and formulation stability with a sufficient shelf life. In some embodiments, the compositions described herein may remain stable for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or more at room temperature (25°C). In some embodiments, the compositions described herein may remain stable for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at elevated temperatures (e.g., from 40°C to 60°C). In some embodiments, the compositions described herein may remain stable for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at 40°C. In some embodiments, the compositions described herein may remain stable for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at 60°C. Stability can be determined by methods known in the art, including, for example, observing the appearance of the formulation, monitoring precipitation, monitoring pH changes, monitoring changes in osmolarity, monitoring the stability of the emulsion phase, monitoring the emulsion droplet size, and the like. In some embodiments, the compositions maintain a pH range of approximately pH 4 to approximately pH 8 for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or more at room temperature (25°C). In some embodiments, the compositions maintain a pH range of approximately pH 4 to approximately pH 8 for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at elevated temperatures (e.g., 40°C to 60°C).In some embodiments, the compositions maintain a pH range of approximately pH 5 to approximately pH 6 for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or longer at room temperature (25°C). In some embodiments, the compositions maintain a pH range of approximately pH 5 to approximately pH 6 for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or longer at elevated temperatures (e.g., from 40°C to 60°C). In some embodiments, the multikinase inhibitor does not precipitate in the compositions for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or longer at room temperature (25°C).In some embodiments, the multikinase inhibitor does not precipitate in the compositions for at least 1 month, 2 months, 3 months, 4 months, 5 months or 6 months or more at elevated temperatures (e.g., from 40°C to 60°C). In some embodiments, the compositions maintain an osmolarity of approximately 250 mOsm / kg to approximately 400 mOsm / kg for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or more at room temperature (25°C). In some embodiments, the compositions maintain an osmolarity of approximately 250 mOsm / kg to approximately 400 mOsm / kg for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at elevated temperatures (e.g., 40°C to 60°C). In some embodiments, at least 99% of the multikinase inhibitor remains dissolved in the composition for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or more at room temperature (25SC). In some embodiments, at least 99% of the multikinase inhibitor remains dissolved in the composition for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at elevated temperatures (e.g., 40°C to 60°C). In some embodiments, at least 99.5% of the multikinase inhibitor remains dissolved in the composition for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or more at room temperature (25SC).In some embodiments, at least 99.5% of the multikinase inhibitor remains dissolved in the composition for at least 1 month, 2 months, 3 months, 4 months, 5 months or 6 months or more at elevated temperatures (e.g., 40eC to 60eC). In some embodiments, 100% of the multikinase inhibitor remains dissolved in the composition for at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 15 months, at least 18 months, at least 24 months, or more at room temperature (25°C). In some embodiments, 100% of the multikinase inhibitor remains dissolved in the composition for at least 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months or more at elevated temperatures (e.g., from 40°C to 60°C). This unique formulation system is also well-tolerated in humans and animals and could be an effective treatment option for various ocular conditions, such as diseases affecting the anterior segment of the eye. Additionally, an emulsion, such as a nanoemulsion, with the addition of thickening agents, such as sodium carboxymethylcellulose or hydroxypropyl methylcellulose, can increase the drug's half-life on the affected ocular surface when administered topically. This results in increased drug residence time on the ocular surface and a decrease in dosing frequency while maintaining pharmaceutically effective treatment. In some embodiments, the disclosure provides an ophthalmic composition comprising a therapeutically effective amount of a multikinase inhibitor (e.g., nintedanib or axitinib or pazopanib), optionally where such a combination of an emulsion, such as a nanoemulsion, with a cyclic oligosaccharide, such as 2-hydroxypropyl-beta-cyclodextrin, as a solubilizer, is suitable for topical administration to the eyes.In some embodiments, a method is provided for treating an ocular condition associated with angiogenesis, such as hyperemia, neovascularization, pterygium, pinguecula, glaucoma filtration surgery and minimally invasive glaucoma surgery (MIGS), corneal transplant surgery with graft rejection, graft-versus-host disease, dry eye disease, atopic conjunctivitis, rosacea, ocular pemphigoid, Lyell's syndrome, Stevens-Johnson syndrome, viral infection (e.g., HSV-1), bacterial infection, fungal infection, parasitic infection, contact lens-induced neovascularization, ulceration, alkali burns, stem cell deficiency, also disclosed herein, and where at least one symptom of the ocular condition is relieved, regressed, or stopped.As used herein, unless otherwise specified, the term nintedanib or axitinib or pazopanib includes its free base, salts, analogues, esters, and combinations thereof. Additionally, the compositions disclosed herein may comprise compounds with a similar pharmacological profile and physical and chemical properties to multikinase inhibitors, such as afatinib, amuvatinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, palbociclib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, and vemurafenib. In some embodiments, the compositions described herein may be useful for treating one or more eye conditions in an affected eye of a subject. Methods comprising administering a composition described herein to an affected eye of a subject are provided herein. In some embodiments, the eye condition may be any condition of an eye resulting from angiogenesis in the anterior or posterior segment of an eye. The subject to be treated may be of any age or sex. In some embodiments, the subject may be a human being. In some embodiments, the subject may be a non-human mammal. In some embodiments, a pharmaceutical composition disclosed herein may include a therapeutically effective amount of an agent described herein. Such effective amounts may be determined based on the effect of the administered agent, or the combined effect of agents if more than one agent is used. A therapeutically effective amount of an agent may also vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual, for example, improvement of at least one parameter of the disorder or improvement of at least one symptom of the disorder. A therapeutically effective amount is also one in which the toxic or harmful effects of the composition are outweighed by the therapeutically beneficial effects.As used herein, a dose is considered effective if it improves, prevents, reduces, or eliminates symptoms associated with the eye condition being treated. In some embodiments, the multikinase inhibitor, such as nintedanib, axitinib, or pazopanib, may be present in the ophthalmic compositions described herein in an amount of approximately 0.001% to approximately 10.0% (w / w). In some embodiments, the multikinase inhibitor is present in an amount of approximately 0.005% to approximately 2% (w / w), approximately 0.001% to approximately 1% (w / w), approximately 0.001% to approximately 0.005% (w / w), approximately 0.005% to approximately 0.01% (w / w), approximately 0.01% to approximately 0.05% (w / w), approximately 0.05% to approximately nrzznn / Lznz / E / YiAi 0.1% (w / w), from approximately 0.01% to approximately 1% (w / w), from approximately 0.05% to approximately 0.5%, from approximately 0.01% to approximately 0.8% (w / w), from approximately 0.3% to approximately 0.7% (w / w), from approximately 0.4% to approximately 0.6% (w / w), from approximately 0.1% to approximately 10% (w / w), from approximately 0.1% to approximately 0.5% (w / w), from approximately 0.2% to approximately 8% (w / w), from approximately 0.4% to approximately 5% (w / w), or from approximately 0.4% to approximately 2% (w / w). In some embodiments, the multikinase inhibitor is present at a concentration of approximately 0.5% (w / w). In some embodiments, the multikinase inhibitor is present at a concentration of approximately 0.2% (w / w). In some embodiments, at least 99% of the multikinase inhibitor is dissolved in the composition.In some embodiments, at least 99.5% of the multikinase inhibitor is dissolved in the composition. In some embodiments, 100% of the multikinase inhibitor is dissolved in the composition. In some embodiments, the disclosed compositions may be emulsions, solutions, suspensions, gels, ointments, occlusive films, or a sustained-release formulation, and may be preserved or non-preserved formulations. In some embodiments, the disclosed compositions may be emulsions. In some embodiments, the disclosed compositions may be nanoemulsions. An emulsion may have any suitable droplet size (e.g., from approximately 10 nm to approximately 10,000 nm, from approximately 100 nm to approximately 500 nm, less than approximately 500 nm, less than approximately 400 nm, less than approximately 300 nm, less than approximately 200 nm, or less than approximately 100 nm). The compositions may be formulated as eye drops, creams, ointments, films, gels, and implants (e.g., a sustained-release implant) that can be applied to an eye.The formulations can be administered to the eye of a subject who needs it. Table 1 lists non-limiting examples of possible formulation ingredients and their example concentrations. nrzznn / Lznz / E / YiAi Table 1 nrzznn / Lznz / Ε / γΐΛ Function Ingredient Composition (% w / w) Active ingredient nintedanib 0.01 - 10.0 axitinib 0.001 - 10.0 pazopanib 0.01 - 10.0 Thickener / Visibility agent carbomer, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, xanthan gum 0-3.0 Antioxidant disodium edetate, dibutylhydroxytoluene, citric acid, sodium metabisulfite, tocopheryl acetate 0-1.0 Surfactant polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, polyoxyl-35 castor oil, polyoxyl-40 castor oil, tocopherol and other polymeric emulsifiers 0-10.0 Lipophilic vehicle castor oil, squalene, isostearyl isostearate, isopropyl myristate, mineral oil, silicone oil, medium chain triglycerides 0-10.0 Function Ingredient Composition (% w / w) Buffering agent sodium citrate dihydrate, sodium citrate boric acid, monosodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, monobasic sodium phosphate monohydrate 0 - 2.0 Tonicity agent glycerin, erythritol, mannitol, potassium chloride, sodium chloride 0-3.0 Solubilizing agent / solubility enhancer cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-betacyclodextrin, 2-hydroxypropyl-alphacyclodextrin, 2-hydroxypropyl-gammacyclodextrin, sulfobutyl ether-betacyclodextrin 0 - 20.0 Preservative benzalkonium chloride, PIP, sorbic acid, PHMB and other ophthalmic preservatives 0 - 2.0 Hydrophilic vehicle water 0 - 99.0 In some embodiments, the composition may comprise a lipophilic vehicle such as castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof. In some embodiments, the lipophilic vehicle may include castor oil. In some embodiments, the lipophilic vehicle may be present in an amount of approximately 0% to approximately 10% of the composition by weight (e.g., from approximately 0.001% to approximately 10% (w / w), from approximately 0.01% to approximately 5.0% (w / w), from approximately 0.05% to approximately 1.0% (w / w), or from approximately 0.1% to approximately 0.5% (w / w)).In some embodiments, the lipophilic vehicle may be present in an amount of approximately 0.25% (w / w). In some embodiments, the composition may comprise one or more surfactants, such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, polyoxyl-35 castor oil, polyoxyl-40 castor oil, tocopherol, other polymeric emulsifiers, or combinations thereof. In some embodiments, the composition may include a surfactant that is a polyoxyl oil, such as a polyoxyl castor oil (e.g., polyoxyl-35 castor oil, polyoxyl-40 castor oil, or a combination thereof) (e.g., a CREMOPHOR® or a KOLLIPHOR®). In some of these embodiments, the composition may further include one or more additional surfactants that are not a polyoxyl oil (for example, a polysorbate, such as polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a combination thereof).In some embodiments, a surfactant may be present in an amount of approximately 0% to approximately 10% by weight of the composition (e.g., from approximately 0.001% to approximately 10% (w / w), from approximately 0.05% to approximately 5% (w / w), from approximately 0.01% to approximately 1.0% (w / w), or from approximately 0.1% to approximately 0.5% (w / w)). In some embodiments, a surfactant may be present in an amount of approximately 0.5% (w / w). In some embodiments, a polyoxyl oil may be present in an amount of approximately 0% to approximately 10% by weight of the composition (e.g., from approximately 0.001% to approximately 10% (w / w), from approximately 0.05% to approximately 5% (w / w), from approximately 0.01% to approximately 1.0% (w / w), or from approximately 0.1% to approximately 0.5% (w / w)).5% (w / w). In some of these embodiments, a second surfactant may be present in an amount of approximately 0% to approximately 10% by weight of the composition (e.g., from approximately 0.001% to approximately 10% (w / w), from approximately 0.05% to approximately 5% (w / w), from approximately 0.01% to approximately 1.0% (w / w), or from approximately 0.1% to approximately 0.5% (w / w)). In some embodiments, the composition may comprise a tonicity agent, such as sodium chloride, glycerin, mannitol, potassium chloride, erythritol, and combinations thereof, in an amount sufficient to maintain the osmolarity in the range of 250 to 400 mOsm / kg (e.g., from approximately 250 to approximately 300 mOsm / kg or from approximately 300 to approximately 400 mOsm / kg). In some embodiments, a tonicity agent may include glycerin. In some embodiments, a tonicity agent may be present in an amount of approximately 0 to approximately 10% by weight of the composition (e.g., from approximately 0% to approximately 3%, from approximately 0.1% to approximately 10% (w / w), from approximately 0.01% to approximately 1% (w / w), or from approximately 0.05% to approximately 0.5% (w / w)). In some embodiments, the tonicity agent may be present in an amount of approximately 0.1% (w / w). In some embodiments, the composition may comprise an antioxidant, such as disodium edetate, dibutylhydroxytoluene, citric acid, sodium metabisulfite, tocopheryl acetate, and combinations thereof. In some embodiments, an antioxidant may be selected from the group consisting of disodium edetate, citric acid, and combinations thereof. In some embodiments, the antioxidant may be present in an amount of approximately 0 to approximately 1% by weight of the composition (e.g., from approximately 0.01% to approximately 1.0% (w / w) or from approximately 0.05% to approximately 0.5% (w / w)). In some embodiments, the antioxidant may be present in an amount of approximately 0.115% (w / w).In some embodiments, the antioxidant may comprise disodium edetate, and the disodium edetate may be present in an amount of approximately 0.01% to approximately 1.0% (w / w), approximately 0.05% to approximately 0.5%, or approximately 0.1% (w / w). In some embodiments, the antioxidant may comprise citric acid, and the citric acid may be present in an amount of approximately 0.001% to approximately 0.1% (w / w), approximately 0.005% to approximately 0.05%, or approximately 0.015% (w / w). nrzznn / Lznz / E / YiAi In some embodiments, the composition may include one or more buffering agents. Suitable buffering agents include, but are not limited to, phosphates, citrates, acetates, borates, and combinations thereof. In some embodiments, the buffering agent may be selected from the group consisting of sodium citrate dihydrate, sodium citrate, monobasic sodium phosphate monohydrate, monosodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, boric acid, and combinations thereof. In some embodiments, the buffering agent may be selected from the group consisting of sodium citrate dihydrate, sodium citrate, and a combination thereof. In some embodiments, the buffering agent may be selected from the group consisting of sodium citrate dihydrate, sodium citrate, or a combination thereof.The amount of buffer component used is sufficient to maintain the pH of the composition within a range of approximately 4 to approximately 8 (e.g., approximately 5.0 to approximately 7.0 or approximately 5.5 to approximately 6.5) throughout the product's shelf life. In certain embodiments, the buffer is present in an amount of approximately 0 to approximately 2.0% by weight of the composition (e.g., approximately 0.01% to approximately 1.0% (w / w) or approximately 0.03% to approximately 0.06% (w / w)). In some embodiments, the buffer is present in an amount of approximately 0.045% (w / w). In some embodiments, the composition may include a thickener or a viscosity modifier. In some embodiments, the viscosity modifier may be selected from carbomer, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose (for example, an HPMC with an average methoxy group content of about 29% and an average hydroxypropyl group content of about 10%), polyvinyl alcohol, xanthan gum, and combinations thereof. In some embodiments, the thickener may be hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or a combination thereof. In some embodiments, the viscosity modifier may be present in an amount of about 0% to about 3% by weight of the composition (for example, about 0.01% to about 1.0% (w / w) or about 0.05% to about 0.5% (w / w)).In some embodiments, the thickener may be present in an amount of approximately 0.1% (w / w). In some embodiments, the composition may include a solubilizing agent or solubility enhancer. In some embodiments, the solubilizer may be a cyclic oligosaccharide. In some embodiments, the solubilizer or solubility enhancer may be selected from cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin (sometimes also called HPBCD or HP-beta-CD), 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether beta-cyclodextrin, and combinations thereof. In some embodiments, the solubilizer may include 2-hydroxypropyl-beta-cyclodextrin.In some embodiments, the solubilizer or solubility enhancer may be present in an amount of approximately 0% to approximately 20% by weight of the composition (e.g., approximately 1% to approximately 20% (w / w), approximately 5% to approximately 15% (w / w), or approximately 8% to approximately 12% (w / w)). In some embodiments, the solubilizer or solubility enhancer may be present in an amount of approximately 10% (w / w). In some embodiments, the composition may be administered topically as eye drops, cream, ointment, film, suspension, gel, or similar. In some embodiments, the composition may be administered to one or both eyes of a subject. The compositions of or used in this disclosure may include one or more other components in amounts effective to provide one or more useful properties and / or benefits. For example, although the compositions presented herein may be substantially free of added preservatives, in other embodiments, the compositions present herein include effective amounts of preservatives. Examples of such preservatives include, but are not limited to, a stabilized oxychloride complex (e.g., PURITE®), quaternary ammonium preservatives such as benzalkonium chloride (BAC or BAK), sorbic acid, and polyoxamer; biguanide preservatives such as polyhexamethylene biguanide-biguanide (PHMB); methyl and ethylparabens; hexetidine; chlorite components such as stabilized chlorine dioxide, metal chlorites, and the like; other ophthally acceptable preservatives; and mixtures thereof.The concentration of the preservative component, if any, in the present compositions is an effective concentration for preserving the composition and is often and generally used in a range of approximately 0% to approximately 2.0% by volume of the composition. Normally, water makes up the rest of the compositions described in this document. Some embodiments in this document provide compositions with nezznn / Lznz / E / YiAi various combinations of ingredients. Illustrative compositions are shown in Table A. Table A. Component Illustrative component Illustrative quantity A1 (w / w) Illustrative quantity A2 (w / w) Illustrative quantity A3 (w / w) Multikinase inhibitor Nintedanib, axitinib or pazopanib Approximately 0.005% Approximately 2% Approximately 0.1% Approximately 0.5% Approximately 0.2% Polyoxyl oil Polyoxyl-35 castor oil Approximately 0.1% Approximately 1% Approximately 0.3% Approximately 0.7% Approximately 0.5% Lipophilic vehicle Castor oil Approximately 0.05% Approximately 1% Approximately 0.1% Approximately 0.5% Approximately 0.25% Solubilizer 2-hydroxypropyl beta-cyclodextrin Approximately 5 % Approximately 15% Approximately 8% Approximately 12% Approximately 10% Additional components may be present in the compositions provided herein. Examples of additional components are shown in Table B. Each combination in Table A and Table B is explicitly covered (e.g., A1B1, A2B1, A3B1, A1B2, A2B2, A3B2, A1B3, A2B3, and A3B3). nrzznn / Lznz / E / YiA Table B. Component Illustrative component Illustrative quantity B1 (w / w) Illustrative quantity B2 (w / w) Illustrative quantity B3 (w / w) Surfactant Polysorbate 80 Approximately 0.05% Approximately 5% Approximately 0.1% to approximately 1% Approximately 0.5% Thickener Hydroxypropyl methylcellulose Approximately 0.01% Approximately 1.0% Approximately 0.05% - approximately 0.5% Approximately 0.1% Buffer Sodium citrate Approximately 0.01% Approximately 1.0% Approximately 0.03% - 0.06% Approximately 0.045% Antioxidant Disodium edetate and / or citric acid Approximately 0.01% Approximately 1.0% Approximately 0.05% - approximately 0.5% Approximately 0.115% Tonicity Agent Glycerin Approximately 0.01% Approximately 1% Approximately 0.05% - approximately 0.5% Approximately 0.1% This document also provides methods for preparing compositions (e.g., emulsions). In some embodiments, the compositions may be any of the compositions described herein. In some embodiments, the methods may include dissolving a multikinase inhibitor in a primary emulsion, reducing the droplet size of the primary emulsion to form a nanoemulsion, and filtering the nanoemulsion. In some embodiments, dissolving the multikinase inhibitor may involve high-shear mixing. In some embodiments, the methods may include forming a primary emulsion, reducing the droplet size of the primary emulsion to form a nanoemulsion, dissolving a multikinase inhibitor in a solution, combining the nanoemulsion and the solution to form a nanoemulsion comprising the multikinase inhibitor, and optionally filtering the nanoemulsion comprising the multikinase inhibitor.In some embodiments, dissolving a multikinase inhibitor in a solution may include dissolving the inhibitor in a solution that includes a solubilizer (e.g., any of the solubilizers described herein). In some embodiments, the solution may further include a buffer (e.g., sodium citrate), an antioxidant (e.g., citric acid and / or trisodium EDTA), a thickener (e.g., HPMC), or a combination thereof. In some embodiments, reducing the droplet size may involve the use of a microfluidizer. Filtration of the nanoemulsion can be performed using a filter of any appropriate size (e.g., a 0.2-micrometer filter). In some embodiments, the method may involve loading the filtered nanoemulsion into sterile dropper bottles. Non-limiting examples of sterile dropper bottles include preservative-free multidose containers (MDSCs) or low-density polyethylene (LDPE) single-dose containers. In some embodiments, a primary emulsion may include a polyoxyl oil, a lipophilic vehicle, and water. In some embodiments, a primary emulsion may further include a surfactant. In some embodiments, a primary emulsion may further include a solubilizer.In some embodiments, a primary emulsion may include one or more of a thickener, a buffering agent, a toning agent, an antioxidant, and combinations thereof. The frequency, duration, and dosage of administration are determined by the prescribing physician. The dosage may vary depending on the dosage formulation. The frequency of administration may be once or more daily (such as once, twice, three, or four or more times daily), every two weeks (such as every two weeks or twice a week), and / or monthly. The duration of administration may continue until the eye condition being treated resolves, that is, until one or more symptoms of the eye condition improve, decrease, or disappear. In some embodiments, a composition described herein may be administered for hours, days, weeks, months, or years. A symptom is considered relieved or improved if it is prevented, reduced, or eliminated. A symptom is prevented in a patient who typically experiences a particular symptom with the eye condition, and the patient does not experience the onset of the symptom after administration of the disclosed composition. A reduction of a symptom is considered achieved if there is a 5%, 10%, 20%, 50%, 75%, 90%, or greater reduction in the severity or duration of one or more symptoms associated with the eye condition in a patient. Elimination of one or more symptoms associated with the eye condition is achieved when it is no longer present or substantially present in a patient. In some embodiments, elimination of one or more symptoms associated with the eye condition is achieved when 90% or more of one or more symptoms are no longer present. Unless otherwise stated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, etc., used in the specification and claims are to be understood as being modified in all cases by the term "approximately." Consequently, unless otherwise stated, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the desired properties sought to be obtained by the present invention. At a minimum, and not in an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be interpreted at least in light of the number of significant digits indicated and by applying customary rounding techniques.Although the numerical ranges and parameters that define the broad scope of the invention are approximations, the numerical values ​​stated in the specific examples are presented as accurately as possible. However, any numerical value inherently contains some errors that are necessarily the result of the standard deviation found in its respective test measurements. References to numerical ranges by means of endpoints include all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.). The terms "a," "an," or "one" and similar referents used in the context of the description of the invention should be interpreted to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by the context. Mention of ranges of values ​​herein is intended only as a shorthand procedure for referring individually to each separate value within the range. nrzznn / Lznz / E / YiAi Unless otherwise stated herein, each individual value is incorporated into the specification as if it were individually mentioned herein. All methods described herein may be performed in any suitable order unless otherwise stated herein or clearly contradicted by the context. The use of any and all examples, or illustrative language (e.g., such as) provided herein is intended merely to better illustrate the invention and has no limitation on the scope of the invention otherwise claimed. Nothing in the specification is to be construed as indicating that any element not claimed is essential to the practice of the invention. Groups of elements or alternative embodiments of the invention disclosed herein are not to be construed as limitations.Each member of the group may be referenced and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or removed from, a group for reasons of convenience and / or patentability. Certain embodiments of the present invention are described herein. Of course, variations of these described embodiments will be evident to those skilled in the art upon reading the foregoing description. The inventor expects those skilled in the art to use such variations as appropriate, and the inventors do not intend for the invention to be put into practice in any manner other than that specifically described herein. Accordingly, the invention includes all modifications and equivalents of the subject matter mentioned in the appended claims as permitted by applicable law. Furthermore, any combination of the elements described above in all possible variations thereof is covered by the invention unless otherwise stated or clearly contradicted by the context. The present invention is not limited to the exact details shown and described. Specific embodiments disclosed herein may be further limited in the claims by using "consisting of" or "consisting essentially of." When used in the claims, whether presented or added by amendment, the transitional expression "consisting of" excludes any element, step, or ingredient not specified in the claims. The transitional expression "consisting essentially of" limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel feature(s). Embodiments of the invention claimed herein are either inherently or expressly described or permitted herein. It should be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be used are within the scope of the invention. Thus, by way of example, but not as a limitation, alternative configurations of the present invention may be used in accordance with the teachings of this document. Example realizations Embodiment 1 is an emulsion comprising: a therapeutically effective amount of a multikinase inhibitor; a polyoxyl oil; a lipophilic vehicle; and water. Realization 2 is the emulsion of realization 1, where the emulsion is a nanoemulsion. Embodiment 3 is the emulsion of any one of embodiments 1 to 2, wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, cñzotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations thereof. Realization 4 is the emulsion of realization 3, wherein the multikinase inhibitor is selected from axitinib, nintedanib, and pazopanib. Realization 5 is the emulsion of realization 3, where the multikinase inhibitor is axitinib. Realization 6 is the emulsion of realization 3, where the multikinase inhibitor is nintedanib. Realization 7 is the emulsion of realization 3, where the multikinase inhibitor is pazopanib. nrzznn / Lznz / E / YiAi Embodiment 8 is the emulsion of any one of embodiments 1 to 7, further comprising a solubilizer. Realization 9 is the emulsion of any one of realizations 1 to 8, wherein the solubilizer is a cyclic polysaccharide. Embodiment 10 is the emulsion of embodiment 4, wherein the cyclic polysaccharide is selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, and combinations thereof. Embodiment 11 is the emulsion of any one of embodiments 1 to 10, wherein the polyoxyl oil is a polyoxyl castor oil. Embodiment 12 is the emulsion of embodiment 11, wherein the polyoxyl castor oil is polyoxyl-40 castor oil, polyoxyl-35 castor oil, or a combination thereof. Embodiment 13 is the emulsion of any one of embodiments 1 to 12, wherein the lipophilic vehicle is selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof. Embodiment 14 is the emulsion of any one of embodiments 1 to 13, further comprising a surfactant selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol and combinations thereof. Realization 15 is the emulsion of realization 1, wherein the multikinase inhibitor is nintedanib, the solubilizer is 2-hydroxypropyl-beta-cyclodextrin, the lipophilic vehicle is castor oil, and the polyoxyl oil is polyoxyl-35 castor oil, or a combination thereof. Realization 16 is the emulsion of any one of realizations 1 to 15, wherein the multikinase inhibitor is present in an amount of approximately 0.001% w / w or approximately 10.0% w / w. Realization 17 is the emulsion of realization 16, wherein the multikinase inhibitor is present in an amount of approximately 0.01% to approximately 1% w / w. Realization 18 is the emulsion of realization 16, wherein the multikinase inhibitor is present in an amount of approximately 0.1% to approximately 0.5% w / w. nrzznn / Lznz / E / YiAi Realization 19 is the emulsion of any one of realizations 1 to 14, wherein the multikinase inhibitor is nintedanib and the nintedanib is present in an amount of approximately 0.01% w / w to approximately 10.0% w / w. Realization 20 is the emulsion of realization 19, wherein nintedanib is present in an amount of approximately 0.01% to approximately 1% w / w. Realization 21 is the emulsion of realization 19, wherein nintedanib is present in an amount of approximately 0.1% to approximately 0.5% w / w. Realization 22 is the emulsion of any one of realizations 1 to 14, wherein the multikinase inhibitor is axitinib and the axitinib is present in the emulsion in an amount of approximately 0.001% w / w or approximately 10.0% w / w. Realization 23 is the emulsion of realization 22, wherein axitinib is present in an amount of approximately 0.01% to approximately 1% w / w. Realization 24 is the emulsion of realization 22, wherein axitinib is present in an amount of approximately 0.05% to approximately 0.5% w / w. Realization 25 is the emulsion of any one of realizations 1 to 14, wherein the multikinase inhibitor is pazopanib and pazopanib is present in an amount of approximately 0.01% w / w or approximately 10.0% w / w. Realization 26 is the emulsion of realization 25, wherein pazopanib is present in an amount of approximately 0.01% to approximately 1% w / w. Realization 27 is the emulsion of realization 25, wherein pazopanib is present in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 28 is the emulsion of any one of embodiments 1 to 27, wherein the lipophilic vehicle is present in an amount of approximately 0.01% w / w or approximately 5.0% w / w. Embodiment 29 is the emulsion of embodiment 28, wherein the lipophilic vehicle is present in an amount of approximately 0.05% to approximately 1% w / w. Realization 30 is the emulsion of realization 28, wherein the lipophilic vehicle is present in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 31 is the emulsion of any one of embodiments 1 to 30, wherein the polyoxyl oil is present in an amount of approximately 0.01% w / w or approximately 10% w / w. Embodiment 32 is the emulsion of embodiment 31, wherein polyoxyl oil is present in an amount of approximately 0.05% to approximately 1% w / w. Embodiment 33 is the emulsion of embodiment 31, wherein polyoxyl oil is present in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 34 is the emulsion of any one of embodiments 1 to 33, further comprising a solubilizer, wherein the solubilizer is present in the emulsion in an amount of approximately 1% w / w to approximately 20% w / w. Embodiment 35 is the emulsion of embodiment 34, wherein the solubilizer is present in an amount of approximately 5% to approximately 15% w / w. Embodiment 36 is the emulsion of embodiment 34, wherein the solubilizer is present in an amount of approximately 8% to approximately 12% w / w. Embodiment 37 is the emulsion of any one of embodiments 1 to 36, further comprising an additional constituent selected from the group consisting of a thickener, a buffering agent, a tonicity agent, an antioxidant, and combinations thereof. Embodiment 38 is the emulsion of embodiment 37, wherein the thickener is selected from the group consisting of carbomer, sodium carboxymethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, polyvinyl alcohol, xanthan gum, and combinations thereof. Embodiment 39 is the emulsion of embodiment 38, wherein the thickener is hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or a combination thereof. Embodiment 40 is the emulsion of any one of embodiments 37-39, wherein the thickener is present in an amount of approximately 0.01% w / w or approximately 1.0% w / w. Embodiment 41 is the emulsion of any one of embodiments 37-39, wherein the thickener is present in an amount of approximately 0.05% w / w or approximately 0.5% w / w. Realization 42 is the emulsion of any one of realizations 37-41, wherein the buffering agent is selected from the group consisting of phosphates, citrates, acetates, borates, and combinations thereof. Embodiment 43 is the emulsion of any one of embodiments 37-42, wherein the buffering agent is selected from the group consisting of sodium citrate dihydrate, sodium citrate, monobasic sodium phosphate monohydrate, monosodium phosphate monohydrate, dibasic sodium phosphate heptahydrate, boric acid, and combinations thereof. nezznn / Lznz / E / YiAi Embodiment 44 is the emulsion of any one of embodiments 37-43, wherein the buffering agent is selected from the group consisting of sodium citrate dihydrate, sodium citrate, or a combination thereof. Embodiment 45 is the emulsion of any one of embodiments 37-44, wherein the buffering agent is present in the emulsion in a sufficient quantity to maintain the pH in the range of 4.0 to 8.0. Embodiment 46 is the emulsion of any one of embodiments 37-44, wherein the buffering agent is present in the emulsion in a sufficient amount to maintain the pH in the range of approximately 5.5 to approximately 6.5. Embodiment 47 is the emulsion of any one of embodiments 37-46, wherein the buffering agent is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. Embodiment 48 is the emulsion of any one of embodiments 37-46, wherein the buffering agent is present in an amount of approximately 0.03% w / w or approximately 0.06% w / w. Realization 49 is the emulsion of any one of realizations 37-48, wherein the antioxidant is selected from the group consisting of disodium edetate, dibutylhydroxytoluene, citric acid, sodium metabisulfite, tocopheryl acetate, and combinations thereof. Realization 50 is the emulsion of any one of realizations 37-48, wherein the antioxidant is selected from the group consisting of disodium edetate, citric acid, and combinations thereof. Embodiment 51 is the emulsion of any one of embodiments 37-50, wherein the antioxidant is present in an amount of approximately 0.01% to approximately 1.0% w / w. Embodiment 52 is the emulsion of any one of embodiments 37-50, wherein the antioxidant is present in an amount of approximately 0.05% to approximately 0.5% w / w. Embodiment 53 is the emulsion of any one of embodiments 37-52, wherein the antioxidant comprises disodium edetate and the disodium edetate is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. Embodiment 54 is the emulsion of any one of embodiments 37-52, wherein the antioxidant comprises disodium edetate and the disodium edetate is present in an amount of approximately 0.05% w / w. Embodiment 55 is the emulsion of any one of embodiments 37-54, wherein the antioxidant comprises citric acid and citric acid is present in an amount of approximately 0.001% to approximately 0.1% w / w. Embodiment 56 is the emulsion of any one of embodiments 37-54, wherein the antioxidant comprises citric acid and citric acid is present in an amount of approximately 0.005% to approximately 0.05% w / w. Realization 57 is the emulsion of any one of realizations 37-56, wherein the tonicity agent is selected from the group consisting of sodium chloride, glycerin, mannitol, potassium chloride, erythritol, and combinations thereof. Realization 58 is the emulsion of any one of realizations 37-56, where the tonic agent is glycerin. Realization 59 is the emulsion of any one of realizations 37-58, wherein the tonicity oil is present in an amount of approximately 0.1% w / w or approximately 10% w / w. Realization 60 is the emulsion of any one of realizations 37-58, wherein the tonicity oil is present in an amount of approximately 0.01% w / w or approximately 1% w / w. Realization 61 is the emulsion of any one of realizations 37-58, wherein the tonicity oil is present in an amount of approximately 0.05% w / w or approximately 0.5% w / w. Realization 62 is the emulsion of any one of realizations 37 to 61, wherein the tonicity agent is present in a sufficient quantity to maintain the osmolarity in the range of 250 to 400 mOsm / kg. Embodiment 63 is the emulsion of any one of embodiments 1-62, wherein the emulsion further comprises a preservative. Embodiment 64 is the emulsion of embodiment 63, wherein the preservative is selected from the group consisting of benzalkonium chloride (BAK), polyhexamethylene biguanide biguanide (PHMB), a stabilized oxychlor complex, sorbic acid, and combinations thereof. Realization 65 is the emulsion of any one of realizations 1-64, wherein the emulsion is free of preservatives. nrzznn / Lznz / E / YiAi Realization 66 is the emulsion of any one of realizations 1-65, wherein the emulsion has an average droplet size of between approximately 10 nm and 100,000 nm. Realization 67 is the emulsion of any one of embodiments 1-66, wherein the emulsion has an average droplet size of 200 nm or less. Realization 68 is the emulsion of any one of realizations 1-67, wherein the emulsion remains stable for at least 6 months at 25SC. Realization 69 is the emulsion of any one of realizations 1-68, wherein the emulsion remains stable for at least 12 months at 25°C. Realization 70 is the emulsion of any one of realizations 1-69, wherein the emulsion remains stable for at least 24 months at 25SC. Realization 71 is the emulsion of any one of realizations 1-70, wherein the emulsion is formulated in the form of an eye drop, a cream, a gel and ointment, a film. Realization 72 is an emulsion comprising: from approximately 0.005% to approximately 2% w / w of a multikinase inhibitor; from approximately 0.1% to approximately 1% w / w of a polyoxyl oil; from approximately 0.05% to approximately 1% w / w of a lipophilic vehicle; of approximately 5% to approximately 15% w / w of a solubilizer; and water. Realization 73 is the emulsion of realization 72, wherein the multikinase inhibitor is present in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 74 is the emulsion of any one of embodiments 72-73, wherein the polyoxyl oil is present in an amount of approximately 0.3% to approximately 0.7% w / w. Embodiment 75 is the emulsion of any one of embodiments 72-74, wherein the lipophilic vehicle is present in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 76 is the emulsion of any one of embodiments 72-75, wherein the solubilizer is present in an amount of approximately 8% to approximately 12% w / w. Realization 77 is an emulsion comprising: of approximately 0.1% to approximately 0.5% w / w of a multikinase inhibitor; from approximately 0.3% to approximately 0.7% w / w of a polyoxyl oil; of approximately 0.1% to approximately 0.5% w / w of a lipophilic vehicle; of approximately 8% to approximately 12% w / w of a solubilizer; and water. Realization 78 is the emulsion of any one of realizations 72-77, wherein the multikinase inhibitor is present in an amount of approximately 0.2% w / w. Embodiment 79 is the emulsion of any one of embodiments 72-78, wherein the polyoxyl oil is present in an amount of approximately 0.5% w / w. Realization 80 is the emulsion of any one of realizations 72-79, wherein the lipophilic vehicle is present in an amount of approximately 0.25% w / w. Embodiment 81 is the emulsion of any one of embodiments 72-80, wherein the solubilizer is present in an amount of approximately 10% w / w. Realization 82 is an emulsion comprising: approximately 0.2% w / w of a multikinase inhibitor; of approximately 0.5% w / w of a polyoxyl oil; approximately 0.25% w / w of a lipophilic vehicle; of approximately 10% w / w of a solubilizer; and water. Embodiment 83 is the emulsion of any one of embodiments 72-83, wherein the multikinase inhibitor is selected from the group consisting of afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations of the same. Realization 84 is the emulsion of any one of realizations 72-83, wherein the multikinase inhibitor is selected from axitinib, nintedanib, and pazopanib. Realization 85 is the emulsion of any one of realizations 72-83, wherein the multikinase inhibitor is axitinib. Realization 86 is the emulsion of any one of realizations 72-83, wherein the multikinase inhibitor is nintedanib. nezznn / Lznz / E / YiAi Realization 87 is the emulsion of any one of realizations 72-83, wherein the multikinase inhibitor is pazopanib. Realization 88 is the emulsion of any one of embodiments 72-87, wherein the solubilizer is a cyclic polysaccharide. Embodiment 89 is the emulsion of embodiment 88, wherein the cyclic polysaccharide is selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, and combinations thereof. Embodiment 90 is the emulsion of any one of embodiments 72-89, wherein the solubilizer comprises 2-hydroxypropyl-beta-cyclodextrin. Embodiment 91 is the emulsion of any one of embodiments 72-90, wherein the polyoxyl oil is a polyoxyl castor oil. Embodiment 92 is the emulsion of embodiment 91, wherein the polyoxyl castor oil is polyoxyl-40 castor oil, polyoxyl-35 castor oil, or a combination thereof. Embodiment 93 is the emulsion of any one of embodiments 72-92, wherein the lipophilic vehicle is selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof. Embodiment 94 is the emulsion of any one of embodiments 72-93, wherein the lipophilic vehicle comprises castor oil. Embodiment 95 is the emulsion of any one of embodiments 72-94, further comprising a surfactant selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol and combinations thereof. Embodiment 96 is the emulsion of embodiment 95, wherein the surfactant is present in an amount of approximately 0.05% to approximately 5% w / w. Embodiment 97 is the emulsion of embodiment 95, wherein the surfactant is present in an amount of approximately 0.1% to approximately 1% w / w. Realization 98 is the emulsion of realization 95, wherein the surfactant is present in an amount of approximately 0.5% w / w. nezznn / Lznz / E / YiAi Embodiment 99 is the emulsion of any one of embodiments 72-98, further comprising an additional constituent selected from the group consisting of a thickener, a buffering agent, a tonicity agent, an antioxidant, and combinations thereof. Embodiment 100 is the emulsion of embodiment 99, wherein the thickener comprises hydroxypropyl methylcellulose, sodium carboxymethylcellulose, or a combination thereof. Embodiment 101 is the emulsion of any one of embodiments 99-100, wherein the thickener is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. Embodiment 102 is the emulsion of any one of embodiments 99-100, wherein the thickener is present in an amount of approximately 0.05% w / w or approximately 0.5% w / w. Realization 103 is the emulsion of any one of embodiments 99-100, wherein the thickener is present in an amount of approximately 0.1% w / w. Embodiment 104 is the emulsion of any one of embodiments 99-103, wherein the buffering agent comprises sodium citrate. Embodiment 105 is the emulsion of any one of embodiments 99-104, wherein the buffering agent is present in the emulsion in a sufficient amount to maintain the pH in the range of approximately 5.5 to approximately 6.5. Embodiment 106 is the emulsion of any one of embodiments 99-105, wherein the buffering agent is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. Embodiment 107 is the emulsion of any one of embodiments 99-105, wherein the buffering agent is present in an amount of approximately 0.03% w / w or approximately 0.06% w / w. Realization 108 is the emulsion of any one of embodiments 99-105, wherein the buffering agent is present in an amount of approximately 0.045% w / w. Embodiment 109 is the emulsion of any one of embodiments 99-108, wherein the antioxidant comprises disodium edetate, citric acid, or a combination thereof. Embodiment 110 is the emulsion of any one of embodiments 99-109, wherein the antioxidant comprises disodium edetate and the disodium edetate is present in an amount of approximately 0.01% w / w to approximately 1.0% w / w. nrzznn / Lznz / E / YiAi Embodiment 111 is the emulsion of any one of embodiments 99-109, wherein the antioxidant comprises disodium edetate and the disodium edetate is present in an amount of approximately 0.05% w / w or approximately 0.5% w / w. Embodiment 112 is the emulsion of any one of embodiments 99-109, wherein the antioxidant comprises disodium edetate and the disodium edetate is present in an amount of approximately 0.1% w / w. Embodiment 113 is the emulsion of any one of embodiments 99-112, wherein the antioxidant comprises citric acid and citric acid is present in an amount of approximately 0.001% to approximately 0.1% w / w. Embodiment 114 is the emulsion of any one of embodiments 99-112, wherein the antioxidant comprises citric acid and citric acid is present in an amount of approximately 0.005% to approximately 0.05% w / w. Embodiment 115 is the emulsion of any one of embodiments 99-112, wherein the antioxidant comprises citric acid and citric acid is present in an amount of approximately 0.015%. Realization 116 is the emulsion of any one of realizations 99-115, wherein the tonic agent comprises glycerin. Realization 117 is the emulsion of any one of realizations 99-116, wherein the tonicity oil is present in an amount of approximately 0.01% w / w or approximately 1% w / w. Realization 118 is the emulsion of any one of realizations 99-116, wherein the tonicity oil is present in an amount of approximately 0.05% w / w or approximately 0.5% w / w. Realization 119 is the emulsion of any one of realizations 99-116, wherein the tonicity agent is present in an amount of approximately 0.1% w / w. Realization 120 is an emulsion comprising: approximately 0.2% w / w of a multikinase inhibitor selected from the group consisting of nintedanib, axitinib, and pazopanib; approximately 0.5% w / w of a polyoxyl castor oil; approximately 0.25% w / w of castor oil; approximately 10% w / w of 2-hydroxypropyl-beta-cyclodextrin; and water. nrzznn / Lznz / E / YiAi Realization 121 is the emulsion of realization 120, wherein the multikinase inhibitor is axitinib. Realization 122 is the emulsion of realization 120, wherein the multikinase inhibitor is nintedanib. Realization 123 is the emulsion of realization 120, wherein the multikinase inhibitor is pazopanib. Embodiment 124 is the emulsion of any one of embodiments 120-123, wherein the polyoxyl castor oil is polyoxyl-40 castor oil, polyoxyl-35 castor oil, or a combination thereof. Embodiment 125 is the emulsion of any one of embodiments 116-124, further comprising polysorbate 80 in an amount of approximately 0.5% w / w. Embodiment 126 is the emulsion of any one of embodiments 120-125, further comprising hydroxypropyl methylcellulose in an amount of approximately 0.1% w / w. Embodiment 127 is the emulsion of any one of embodiments 120-126, further comprising sodium citrate in an amount of approximately 0.045% w / w. Embodiment 128 is the emulsion of any one of embodiments 120-127, further comprising disodium edetate in an amount of approximately 0.1% w / w. Embodiment 129 is the emulsion of any one of embodiments 120-128, further comprising citric acid in an amount of approximately 0.015%. Embodiment 130 is the emulsion of any one of embodiments 120-129, further comprising glycerin in an amount of approximately 0.1% w / w. Embodiment 131 is a method for prolonging the residence time of a multikinase inhibitor on the ocular surface comprising administering the emulsion of any one of embodiments 1-130 to the eye of a subject. Implementation 132 is the method of implementation 131, wherein administration comprises applying the emulsion to the eye at least once a day. Implementation 133 is the method of implementation 131, wherein administration comprises applying the emulsion to the eye at least twice a day. Implementation 134 is the method of implementation 131, wherein administration comprises applying the emulsion to the eye at least three times a day. Implementation 135 is a method for treating an eye condition, comprising administering the emulsion of any one of implementations 1-130 to the eye of a subject. Realization 136 is the method of realization 135, where the eye condition is associated with angiogenesis. Realization 137 is the method of realization 135, wherein the eye condition is selected from the group consisting of hyperemia, neovascularization, pterygium, pinguecula, glaucoma filtration surgery and minimally invasive glaucoma surgery (MIGS), corneal transplant surgery with graft rejection, graft-versus-host disease, dry eye disease, atopic conjunctivitis, rosacea, ocular pemphigoid, Lyell's syndrome, Stevens-Johnson syndrome, viral infection (e.g., HSV-1), bacterial infection, fungal infection, parasitic infection, contact lens-induced neovascularization, ulceration, alkali burns, and stem cell deficiency. Realization 138 is the method of any one of realizations 131-137, wherein the emulsion remains stable for at least 1 month at 40eC. Realization 139 is the method of any one of realizations 131-137, wherein the emulsion remains stable for at least 6 months at 409C. Embodiment 140 is a method for preparing the emulsion of any one of embodiments 1-130, the method comprising: form a primary emulsion; reduce the size of the primary emulsion droplets to form a nanoemulsion; dissolve a multikinase inhibitor in a solution; combine the nanoemulsion and the solution to form a nanoemulsion comprising the multikinase inhibitor; and optionally, filter the nanoemulsion comprising the multikinase inhibitor. Implementation 141 is a method for preparing an emulsion, the method comprising: forming a primary emulsion; reduce the size of the primary emulsion droplets to form a nanoemulsion; dissolve a multikinase inhibitor in a solution; combine the nanoemulsion and the solution to form a nanoemulsion comprising the multikinase inhibitor; and optionally, filter the nanoemulsion comprising the multikinase inhibitor. Embodiment 142 is the method of embodiment 140 or embodiment 141, wherein the formation of the primary emulsion comprises high shear mixing. nrzznn / Lznz / E / YiAi Embodiment 143 is the method of any one of embodiments 140-142, wherein reducing the droplet size comprises the use of a microfluidizer. Embodiment 144 is the method of any one of embodiments 140-143, wherein the filtering comprises the use of a 0.2 micrometer filter. Embodiment 145 is the method of any one of embodiments 140-144, wherein the method further comprises loading the filtered nanoemulsion into sterile dropper bottles. Embodiment 146 is the method of embodiment 145, wherein the sterile dropper bottles are preservative-free multidose containers (MDSC) or low-density polyethylene (LDPE) single-dose containers. Embodiment 147 is the method of any one of embodiments 140-146, wherein the primary emulsion comprises: a polyoxyl oil; a lipophilic carrier; and nezznn / Lznz / E / YiAi water. Embodiment 148 is the method of any one of embodiments 140-147, wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, cñzotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations thereof same. Realization 149 is the method of realization 148, wherein the multikinase inhibitor is selected from axitinib, nintedanib, and pazopanib. is is The realization of axitinib. The realization nintedanib. The pazopanib realization. 150 151 152 is the method of realization 148, where the multikinase inhibitor 148, where the multikinase inhibitor 148, where the multikinase inhibitor Embodiment 153 is the method of any one of embodiments 140 to 152, wherein the solution further comprises a solubilizer. Embodiment 154 is the method of embodiment 153, wherein the solubilizer is a cyclic polysaccharide. Embodiment 155 is the method of embodiment 154, wherein the cyclic polysaccharide is selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin, and combinations thereof. Embodiment 156 is the method of any one of embodiments 147 to 155, wherein the polyoxyl oil is a polyoxyl castor oil. Embodiment 157 is the emulsion of embodiment 156, wherein the polyoxyl castor oil is polyoxyl-40 castor oil, polyoxyl-35 castor oil, or a combination thereof. Embodiment 158 ​​is the method of any one of embodiments 147 to 157, wherein the lipophilic vehicle is selected from the group consisting of castor oil, squalane, diethylene glycol monoethyl ether, propylene glycol, isostearyl isostearate, isopropyl myristate, dipropylene glycol dimethyl ether, diethylene glycol, dipropylene glycol, mineral oil, silicone oil, caprylic / capric triglycerides, medium-chain triglycerides, and combinations thereof. Embodiment 159 is the method of any one of embodiments 147 to 158, wherein the primary emulsion further comprises a surfactant selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol, and combinations thereof. Embodiment 160 is the method of any one of embodiments 147-159, wherein the multikinase inhibitor is nintedanib, the solubilizer is 2-hydroxypropyl-beta-cyclodextrin, the lipophilic vehicle is castor oil, and the polyoxyl oil is polyoxyl-35 castor oil, or a combination thereof. Implementation 161 is the method of any one of implementations 140 to 160, wherein the multikinase inhibitor is present in the primary emulsion in an amount of approximately 0.001% w / w or approximately 10.0% w / w. Implementation 162 is the method of Implementation 161, wherein the multikinase inhibitor is present in the primary emulsion in an amount of approximately 0.01% to approximately 1% w / w. Implementation 163 is the method of Implementation 161, wherein the multikinase inhibitor is present in the primary emulsion in an amount of approximately 0.1% to approximately 0.5% w / w. nrzznn / Lznz / E / YiAi Embodiment 164 is the method of any one of embodiments 147 to 163, wherein the lipophilic vehicle is present in the primary emulsion in an amount of approximately 0.01% w / w to approximately 5.0% w / w. Embodiment 165 is the method of embodiment 164, wherein the lipophilic vehicle is present in the primary emulsion in an amount of approximately 0.05% to approximately 1% w / w. Embodiment 166 is the method of embodiment 164, wherein the lipophilic vehicle is present in the primary emulsion in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 167 is the method of any one of embodiments 147 to 166, wherein the polyoxyl oil is present in the primary emulsion in an amount of approximately 0.01% w / w to approximately 10% w / w. Embodiment 168 is the method of embodiment 167, wherein polyoxyl oil is present in the primary emulsion in an amount of approximately 0.05% to approximately 1% w / w. Embodiment 169 is the method of embodiment 167, wherein polyoxyl oil is present in the primary emulsion in an amount of approximately 0.1% to approximately 0.5% w / w. Embodiment 170 is the method of any one of embodiments 140 to 169, wherein the primary emulsion further comprises a solubilizer, wherein the solubilizer is present in the primary emulsion in an amount of approximately 1% w / w or approximately 20% w / w. Embodiment 171 is the method of embodiment 170, wherein solubilizer is present in the primary emulsion in an amount of approximately 5% to approximately 15% w / w. Embodiment 172 is the method of embodiment 170, wherein solubilizer is present in the primary emulsion in an amount of approximately 8% to approximately 12% w / w. Embodiment 173 is the method of any one of embodiments 147 to 172, wherein the primary emulsion further comprises an additional constituent selected from the group consisting of a thickener, a buffering agent, a tonicity agent, an antioxidant, and combinations thereof. nezznn / Lznz / E / YiAi Realization 174 is the method of any one of realizations 141-173, wherein the filtered emulsion is the emulsion of any one of realizations 1-130. EXAMPLES Example 1. Stability of the emulsion formulation. Solution A and Emulsion B were prepared and their stability was evaluated. Solution A: 0.2% nintedanib in a solution system with 10% 2-hydroxypropyl beta-cyclodextrin. Emulsion B: 0.5% nintedanib in an emulsion system with 5% 2-hydroxypropyl beta-cyclodextrin, castor oil, polysorbate 80, and polyoxyl-35 castor oil. Stability data under accelerated temperature conditions (40°C, 50°C, and 60°C) can be used to extrapolate and predict long-term storage at room temperature. As shown in Table 2, the multikinase inhibitor remained stable in Emulsion B when stored at 40°C, 50°C, and 60°C, indicating that this formulation system could potentially maintain a shelf life of 2 years or more at room temperature. The typical desired shelf life at room temperature for topical eye solutions is 2 years. nrzznn / Lznz / E / YiAi Table 2. Formulation Storage Condition % Normalized Recovery to Initial To (To) 1 Day 4 Days 7 Days 14 Days 1-M 3-M 5-M 9-M Solution A 25 °C 100.0 ND ND ND ND 96.6 94.5 98.3 80.2 Solution A 40 °C 100.0 100.3 89.2 68.8 ND ND ND ND ND Emulsion B 40 °C 100.0 ND ND 97.9 97.3 99.0 ND ND ND Emulsion B 50 °C 100.0 ND ND 97.3 98.9 97.4 ND ND ND Emulsion B 60 °C 100.0 ND ND 93.2 96.2 95.7 ND ND ND Example 2: Synergistic effect of the emulsion system of castor oil, polysorbate 80, polyoxyl-35 castor oil, and 2-hydroxypropyl-beta-cyclodextrin on the solubility of nintedanib. Table 3: Maximum solubility of CBT-001 (nintedanib-free base) in solvents Solvents Maximum solubility (mg / g) Castor oil 0.37 Polysorbate 80 at 1% 0.25 Polyoxyl-35 castor oil 0.29 Solvents Maximum solubility (mg / g) 10% 2-hydroxypropyl-beta-cyclodextrin 2.0 Maximum possible theoretical solubility of nintedanib in the mixture of castor oil, polysorbate 80 and polyoxyl-35 castor oil 0.91 Maximum possible theoretical solubility of nintedanib in the mixture of castor oil, polysorbate 80, polyoxyl-35 castor oil and 2-hydroxypropyl-beta-cyclodextrin 2.91 Measured solubility of nintedanib in the mixture of the nanoemulsion system of 0.25% castor oil, 1% castor oil, 1% polysorbate 80 and 2% polyoxyl-35 castor oil 3.4-5.0 Measured solubility of nintedanib in the mixture of 10% 2-hydroxypropyl-beta-cyclodextrin and system of 0.25% castor oil nanoemulsion, 1% polysorbate 80 and 2% polyoxyl-35 castor oil 7.9 nrzznn / Lznz / E / YiAi According to the FDA's guidance on industry drug stability guidelines, the stability of formulations can be predicted for long-term storage under accelerated (high) temperature conditions. Stability data under accelerated temperature conditions can be used to extrapolate and predict the long-term storage stability of the drug when stored under recommended storage conditions (ideally at room temperature). The maximum solubility of nintedanib in 10% 2-hydroxypropyl-beta-cyclodextrin was approximately 0.2%. Nintedanib 0.2% in 10% 2-hydroxypropyl-beta-cyclodextrin was shown to be stable at room temperature for approximately 5 months and fell below the acceptable stability specification (90% recovery) after 5 months. Under accelerated storage conditions (40°C), it was unstable by day 4. The % recovery of nintedanib fell below 90% on day 4 and below 70% on day 7. This indicates that nintedanib 0.2% in 10% 2-hydroxypropyl-beta-cyclodextrin solution may experience stability issues when stored for 1 to 2 years. The nanoemulsion system and 5% 2-hydroxypropyl-beta-cyclodextrin were used to improve the concentration and stability of nintedanib in the formulation system. Nintedanib at 0.5% in 5% 2-hydroxypropyl-beta-cyclodextrin and the nanoemulsion system were shown to be stable when stored at 40°C, 50°C, and 60°C. This indicates that the 5% 2-hydroxypropyl-beta-cyclodextrin nanoemulsion system had synergistic effects on the stability of nintedanib in the nanoemulsion formulation system. The maximum solubilities of nintedanib in each solvent are listed in Table 3. A theoretical maximum possible solubility of nintedanib in the mixture can be extrapolated by assuming that nintedanib dissolves in each solvent, and then each component is combined to make a mixture of all ingredients. Thus, the theoretical maximum possible solubility of nintedanib in the mixture would be 2.91 mg / g. Unexpectedly, in the formulation system of 10% 2-hydroxypropyl-beta-cyclodextrin and a nanoemulsion of castor oil, 1% polysorbate 80, and 2% polyoxyl-35 castor oil, a better solubility of 7.9 mg / g of nintedanib was achieved. This indicated that 10% 2-hydroxypropyl-beta-cyclodextrin and the nanoemulsion of castor oil, 1% polysorbate 80 and 2% polyoxyl-35 castor oil had synergistic effects on the solubility of nintedanib. Example 3 Nintedanib solubilizers were investigated according to the following procedure: 1. Tare 1.5 ml Eppendorf tubes 2. Add nintedanib and record the weight 3. Add solubilizer and record the weight 4. Add water at pH 5 (except F3 and F4) and record the weight 5. Mix Beadbeater for 120 seconds 6. Place in a rotary mixer overnight at room temperature 7. Filter through a 0.2 pm SPIN-X centrifuge filter 8. Measure the pH of the filtrate 9. Filtration test with standard solution CBT-001 Surprisingly, very different results were found for the investigated solubilizers, even though many of them had similar structural properties (see, for example, Tables 4 and 5). Surprisingly, solubilizers such as castor oil and polysorbate 80 (see, for example, Table 3) were found to have high solubilization yields for nintedanib. Table 4. Compositions analyzed (% by weight) nrzznn / Lznz / E / YiAi % WEIGHT F-1 F-2 F-3 F-4 F-5 F-6 F-7 F-8 F-9 F-10 F-11 F-12 Nintedanib 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Benzyl alcohol 1 Ethanol 1 Castor oil 99.5 Mineral oil 99.5 BZK 1 Polysorbate 20 1 Polysorbate 80 1 Poloxamer 188 1 Poloxamer 407 1 PEG 400 5 PEG 8000 2 Propylene glycol 1 WFI 98.5 98.5 98.5 98.5 98.5 98.5 98.5 94.5 97.5 98.5 Table 5. Solubility of nintedanib in various solubilizers Solubilizer Nintedanib Solubility (mg / g) pH BZA 0.01 5.6 EtOH 0.01 6.1 Castor Oil 0.37 - Mineral Oil 0.00 - BZK 0.20 5.6 Polysorbate 20 0.06 6.6 Polysorbate 80 0.25 6.7 PLXMR 188 0.01 6.5 PLXMR 407 0.01 6.3 PEG 400 0.17 5.6 PEG 8000 0.01 6.0 PG 0.01 6.0 Several emulsion systems were identified for investigation based on the solubilizer results. Surprisingly, emulsion systems combining castor oil, polysorbate 80, and polyoxyl-35 castor oil were found to adequately solubilize nintedanib. As shown in Table 6, one of the emulsion systems can surprisingly dissolve nintedanib at approximately 3–5 mg / mL, a much higher amount than the previously calculated upper theoretical limit (see Table 3) for nintedanib solubility in this combination. Table 6. Solubility of nintedanib in a representative emulsion system. nezznn / Lznz / E / YiAi ID F70 lot 1 F70 lot 2 Castor oil 1 1 Polysorbate 80 1 1 Polyoxyl-35 castor oil 2 2 Water 95 95 Nintedanib solubility (mg / ml) 5 3.4 Example 4 Emulsion systems were identified to develop formulations for nintedanib and other multikinase inhibitors that have physicochemical properties similar to nintedanib. When oil and water are mixed, the common phenomenon after a short period is phase separation. Formulations exhibiting phase separation are unsuitable for certain ocular formulations, such as eye drops. Several emulsion systems were investigated to determine their physical stability and uniformity for potential use in developing ocular formulations for nintedanib and other multikinase inhibitors with similar physicochemical properties. As shown in Table 7, surprisingly, some emulsion systems were found to exhibit phase stability while others were unstable after three days, despite having components with similar properties. The reason why some systems are stable while others are not has not been determined. The following procedure was followed to investigate the physical stability of the emulsion systems: 1. Adjust 100 ml of water to pH 5 2. Tare the 15 ml tube 3. Add materials and record the weights 4. CS with water 5. Vortex to mix for 1 minute 6. Mix with high shear until a uniform emulsion is formed 7. Record the appearance and pH 8. Aliquot each formulation into three 1.5 ml tubes 9. Store at -20°C, 2-8°C and 40°C for 3 days 10. Remove from storage and equilibrate to room temperature 11. Record the appearance 12. Take only the vehicles that are uniform single-phase emulsions and transfer them to the centrifuge. 13. Centrifuge for 10 minutes at 13K RPM. 14. Record the appearance 15. Measure the pH of vehicles that are uniform single-phase emulsions nezznn / Lznz / E / YiAi Table 7. Stability results of various excipient combinations ID F13 F14 F15 F16 F17 F18 F19 F20 Polysorbate 60 15 15 15 15 Polysorbate 80 4 4 4 4 ASpan 20 0.5 0.5 GMS 0.5 0.5 Myrj 52 7 7 Polyoxyl-35 castor oil 5 5 Castor oil 5 5 5 5 5 5 5 5 Water 79.5 79.5 73 75 90.5 90.5 84 86 Formulation observation on day 3 Uniform Separation Uniform Uniform Separation Separation Uniform Uniform The F20 emulsion system was selected as the base system for further formulation development. Example 5 In this example, it was determined that a cyclodextrin-based solubilizing system mixed with the selected castor oil, castor oil, polysorbate 80, and polyoxyl-35 emulsion system was compatible and did not cause failures or phase separation. Additionally, emulsion formulations containing HPbeta-CD, castor oil, polysorbate 80, and polyoxyl-35 castor oil were found to achieve superior stability compared to solution formulations. Without wishing to be bound to any particular theory, it is believed that the complex interactions between the drug and all these ingredients led to this superiority over single-component formulations. This surprising finding was determined through extensive, thorough, and sophisticated experimentation that examined many ingredients sequentially to select the final combination. The superior compositions were determined after several rounds of testing.For example, Emulsion C showed very good stability at high temperatures (>40°C) for several months, indicating that the formulations will have good stability during long-term storage at room temperature. These results were surprising because the solution formulations were found to be unstable under the same conditions, and the earlier emulsion formulations investigated were also found to be less stable. As illustrated in Table 8, just over half of the nintedanib in the solution formulation remained after 1 month at 40°C, whereas almost all of the nintedanib remained in Emulsion C after 6 months under the same conditions. Table 8 also showed that Emulsion C maintained surprisingly stable nintedanib for at least 3 months even at much higher temperatures of 50°C and 60°C.These results were surprising because the solution formulations were found to be unstable under the same conditions; just over half of the nintedanib in the solution formulation remained after 4 weeks at 40°C, while all of the nintedanib remained in Emulsion C after 6 months under the same conditions (Table 8). The same type of emulsion system also kept axitinib, another class of MKI compound, stable for at least 3 months at 40, 50, and 60°C, indicating the likelihood of long-term stability under room temperature storage conditions (Table 9). Emulsion formulation development method The initial development involved the design, preparation, and testing of multiple emulsion compositions for drug solubilization, evaluating droplet size and accelerated physical stability of the emulsion (size change or aggregation). Each test composition contained the basic components, including the API (e.g., nintedanib), oil, surfactant(s), solubilizer, emulsifier(s), lubricant, osmotic agent, and water. From the initial work, 2–3 compositions were selected, modified as needed, and evaluated for viscosity, osmotic pressure, and physical stability of the emulsion. One sample composition was selected for further evaluation after meeting predefined requirements. A pilot-scale manufacturing process was developed to produce the Prototype Formulation with a batch size of 0.1–1 L. The manufacturing procedure included: (1) dissolving the API in a primary emulsion using a high-shear mixer, (2) reducing the droplet size to the target size using a microfluidizer, (3) passing the nanoemulsion through a 0.2-micrometer filter, and (4) loading the nanoemulsion into sterile dropper bottles (preservative-free multi-dose containers or single-dose MDSC and LDPE containers) in a biosafety cabinet. Batches (approximately 250 mL) of the Prototype Formulation were prepared at each of the four concentrations (0%, 0.05%, 0.2%, and 0.5%). Using an aseptic technique, the prototype formulation batches were loaded into 5.5 ml Aptar dropper bottles (3 ml / bottle) or into an LDPE single-dose container (0.3 ml / unit). For each batch concentration, the formulations were tested for pH, appearance (visual and microscopic), osmotic pressure, viscosity, droplet size, API concentration, and impurities. These test results were used as baseline values ​​for the stability test (T = 0). For each batch concentration, the prototype formulations were placed in stability chambers at various temperatures for several time periods. Stability tests were performed on appearance (visual and microscopic), particulate matter (count), droplet size, drug concentration, impurities / degradation products, osmolarity, and pH at selected time points. The Emulsion C, F134 and F135 formulations were prepared as follows: Part 1: Oil / surfactant emulsion 1. Tare a 50ml Falcon tube 2. Add 1.25 g of castor oil 3. Add 0.250 g of Tween 80 4. Add 0.250 g of polyoxyl-35 castor oil 5. Heat the mixture to 50°C in a sonicator and then vortex until uniform and transparent. 6. Add 13.25 g of deionized water 7. Homogenize the mixture at high speed until the oil droplet size is less than 100 nm. Mixing speed: 4,000 RPM Mixing time: 30 minutes Emulsion C Z-Average: 35 nm F-134 Z-Average: 37 nm F-135 Z-Average: 33 nm Part 2: Nintedanib, Axitinib and Pazopanib in HP-beta-CD solution 1. Tare a 50ml Falcon tube 2. Add 25 g of deionized water to a container. 3. While stirring, add 5.0 g of HP-beta-CD and stir until completely dissolved. 4. Add 0.008 g of citric acid and stir until completely dissolved. 5. Add 0.100 g of API to the mixture 6. Sonicate the mixture for 15 minutes and shake in a vortex until completely dissolved. 7. Add 0.023 g of sodium citrate to the mixture and mix until completely dissolved. 8. Add 0.050 g of trisodium EDTA to the mixture and mix until completely dissolved. 9. While stirring the mixture, slowly add 0.050 g of HPMC and mix until completely dissolved. Part 3. The formulations of Emulsion C, F134 and F135 1. Tare a 100 ml glass bottle 2. Add the aqueous solution (part 2) 3. Add the oil emulsion (part 1) 4. Add 5 g of deionized water 5. Add 0.05 g of glycerin to the mixture and mix well. 6. Adjust the pH to 6.0 using 1N NaOH or 1N HCl. Emulsion C Initial pH: 6.66 Final pH: 5.87 F-134 Initial pH: 2.51 Final pH: 6.12 nrzznn / Lznz / E / YiAi F-135 Initial pH: 1.24 Final pH: 6.03 7. Add 50 g of deionized water and mix. Part 4. Filter and load 1. Aseptically filter the formulations through a sterile 0.2 µm syringe filter into a sterile container 2. Aseptically load 5 ml of formulation into 5 type 1 glass vials of 10 ml each 3. Cover the vials with rubber stoppers and seal. 4. Store 2 vials of each formulation at 2-8, 25, 40, 50 and 60 °C 5. Monitor ppt for 1 week The final concentrations of CBT-001 (nintedanib) and excipients in the formulations were determined for the following formulations: Solution A: 0.2% nintedanib in a solution system with 10% 2-hydroxypropyl-beta-cyclodextrin. Emulsion C: 0.2% nintedanib in an emulsion system with 10% 2-hydroxypropyl-beta-cyclodextrin, castor oil, polysorbate 80, polyoxyl-35 castor oil. Table 8. Accelerated laboratory stability of Emulsion C compared to Solution A. The percentage of nintedanib remaining is shown at each time point. Formulation Storage Condition % Normalized Recovery to Initial To (To) 14 Days 1-M 3-M 5 or 6-M 9-M Solution A 25 °C 100.0 ND 101.1 98.2 94.9* 81.2 Solution A 40 °C 100.0 ND 55.2 62.1 69.6* ND Emulsion C 25 °C 100.0 101.4 99.9 99.1 103.3L Emulsion C 40 °C 100.0 101.2 100.9 105.0 112.0L ND Emulsion C 50 °C 100.0 101.8 101.4 110.7 ND ND Emulsion C 60 °C 100.0 100.7 101.0 113.9 ND ND *5 months; 6 months In addition to nintedanib, another multikinase inhibitor, axitinib, was investigated and surprisingly showed good stability at high temperatures for 3 months in a similar emulsion (Table 9). The experiment showed that multikinase inhibitors with similar physical and chemical properties, such as nintedanib and axitinib, can be formulated in certain similar emulsion formulations for long-term storage. Table 9. Accelerated laboratory stability of axitinib in a representative emulsion (F134). The percentage of axitinib remaining is shown at each time. Formulation Temp Day 1 (To) Week 2 Week 4 Week 8 Week 12 F134 (axitinib emulsion) 40 °C 100 97.9 100.3 98.3 105.1 50 °C 100 99.7 101.8 99.5 112.9 60 °C 100 102.8 102.5 100.0 114.0 Example 6 The emulsion formulations, used at the same concentration, are superior to a solution formulation in terms of efficacy and ocular pharmacokinetic profiles in a rabbit model of corneal neovascularization (CNV), while the emulsion and solution formulations share a similar safety profile. The solution formulation used in the study had already been shown to be safe and effective in a human clinical trial. Study summary The study evaluated the efficacy of emulsion and solution formulations in inhibiting hyperemia and neovascularization in the rabbit corneal suture model after 7 days of twice-daily (BID) topical ocular dosing of nintedanib 0.2% emulsion, axitinib 0.05% emulsion, and pazopanib 0.1% emulsion, or three-times-daily (TID) dosing of nintedanib 0.2% solution and vehicle emulsion. The solution was as described in Example 5. The emulsion was very similar to Emulsion C in Example 5. Systemic and ocular pharmacokinetics and ocular tolerability were also evaluated in these animals. All formulations tested were well tolerated ocularly and systemically. Although rabbits received less frequent twice-daily (BID) doses of a 0.2% nintedanib emulsion compared to three times daily (TID) doses of a 0.2% nintedanib solution, the BID 0.2% nintedanib emulsion surprisingly showed similar or better efficacy than the TID 0.2% nintedanib solution, as shown in Figure 2. By day 10, the efficacy of the emulsion and solution was similar. By day 12, the emulsion was statistically more effective than the solution (p = 0.0025). The ocular pharmacokinetic profile indicated that the emulsion can deliver more drug to the target tissues of the conjunctiva and cornea with higher Cmax and AUC (Table 10). Further analysis of the concentration / IC50 relationship over time indicates that the emulsion may have more effective inhibition of the VEGFR2 target, as a ratio >10 would almost completely inhibit the target (Table 11). This demonstrated that the 0.2% nintedanib emulsion is superior to the 0.2% nintedanib solution in delivering more drug to the ocular surface, resulting in improved efficacy and a longer duration of action. Table 10. Comparison of pK between the emulsion and the nintedanib solution nezznn / Lznz / E / YiAi Comparison of the pK of solution formulations versus emulsion formulations Cmax (ng / g) Tmax (h) AUCo-ultimate (ng*h / g) Conjunctiva 0.2% Solution TID 438 ± 82 0.5 1620 0.2% Emulsion BID 763 ± 170 0.5 3982 Cornea 0.2% Solution TID 704 ± 884 0.5 3982 0.2% Emulsion BID 1142 ± 326 0.5 8316 Table 11. Concentration / IC5o relationship of VEGFR2 of the two nintedanib formulations EGFR2 Concentration / IC5° Relationship Time (h) 0.5 2 6 12 Conjunctiva 0.2% Solution TID 38.6 23.6 5.6 3.7 0.2% Emulsion BID 67.3 48.2 19.1 18.5 Cornea 0.2% Solution TID 42.4 53.4 62.1 8.5 0.2% Emulsion BID 100.7 62.6 70.0 36.8 Example 7 The effectiveness of the surfactants PEG-40 stearate and polyoxyl-35 castor oil was investigated to determine their performance in emulsion systems. The compositions investigated are shown in Table 12. Table 12. Composition of formulations F70 and F72. F70 F72 CBT001 (mg / ml) 10 10 Castor oil 1 1 Polysorbate 80 1 1 PEG40 stearate 2 Polyoxyl-35 castor oil 2 HP-beta-CD Water 95 95 nezznn / Lznz / E / YiAi Formulations F70 and F72 (Table 12) were prepared and investigated as follows. 1. Adjust the pH of 100 ml of water to pH 2.0 using 1N HCl pH. 2. Label the 15 ml conical tube. 3. Tare the conical tube. 4. Add water and record the weight. 5. Vortex until a clear solution is obtained. 6. Add Tween 80 castor oil and Polyoxyl-35 or PEG40 stearate and record the weight. 7. Add castor oil and record the weight. 8. Vortex for 1 minute. 9. Mix with high shear into a clear or uniform solution. 10. Add the API. 11. Place the conical tube in an ice bath. 12. Mix with high shear for 30 minutes. 13. After 30 minutes, centrifuge to force the undissolved API to the bottom of the tube. 14. Collect 50 μI from the top of the emulsion and test the droplet size with LLS. 15. If it is greater than 200 nm, continue mixing with high shear and test again. 16. Record the final droplet size. 17. Measure the pH. 18. If it is below pH 6, adjust to pH 6 with 1N NaOH. If the pH is between 6 and 8, do not adjust. 19. Filter through a 0.2 pm syringe filter. 20. Measure the pH and particle size of the filtrate. 21. Test with standard solution CBT-001 (nintedanib). The results of this experiment are shown in Table 13. Because a higher concentration of nintedanib was achieved in formulation F70 than in formulation F72, it is believed that the combination of polyoxyl-35 castor oil and polysorbate 80 is a better surfactant system compared to the combination of PEG40 stearate and polysorbate 80 for emulsifying castor oil to dissolve nintedanib. Table 13. Results nrzznn / Lznz / E / YiAi F F70 F72 Nintedanib concentration (mg / ml) 5.2 1.5

Claims

1. An emulsion characterized in that it comprises: a therapeutically effective amount of a multikinase inhibitor; a polyoxyl oil; a lipophilic vehicle; and water.

2. The emulsion according to claim 1, wherein the multikinase inhibitor is selected from afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations thereof.

3. The emulsion according to claim 2, wherein the multikinase inhibitor is selected from axitinib, nintedanib, and pazopanib.

4. The emulsion according to any one of claims 1 to 3, further comprising a solubilizer.

5. The emulsion according to any one of claims 1 to 4, wherein the solubilizer is a cyclic polysaccharide.

6. The emulsion according to any one of claims 1 to 5, wherein the polyoxyl oil is a polyoxyl castor oil.

7. The emulsion according to claim 6, wherein the polyoxyl castor oil is polyoxyl-40 castor oil, polyoxyl-35 castor oil or a combination thereof.

8. The emulsion according to any one of claims 1 to 7, further comprising a surfactant selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, polyoxyl-40 stearate, tocopherol and combinations thereof.

9. The emulsion according to claim 1, wherein the multikinase inhibitor is nintedanib, the solubilizer is 2-hydroxypropyl-beta-cyclodextrin, the lipophilic vehicle is castor oil, and the polyoxyl oil is polyoxyl-35 castor oil, or a combination thereof.

10. The emulsion according to any one of claims 1 to 9, wherein the multikinase inhibitor is present in an amount of approximately 0.001% w / w to approximately 10.0% w / w.

11. An emulsion characterized in that it comprises: from approximately 0.005% to approximately 2% w / w of a multikinase inhibitor; from approximately 0.1% to approximately 1% w / w of a polyoxyl oil; from approximately 0.05% to approximately 1% w / w of a lipophilic vehicle; from approximately 5% to approximately 15% w / w of a solubilizer; and water.

12. The emulsion according to claim 11, wherein the multikinase inhibitor is present in an amount of approximately 0.1% to approximately 0.5% w / w.

13. The emulsion according to any one of claims 11-12, wherein the polyoxyl oil is present in an amount of approximately 0.3% to approximately 0.7% w / w.

14. The emulsion according to any one of claims 11-13, wherein the lipophilic vehicle is present in an amount of approximately 0.1% to approximately 0.5% w / w.

15. The emulsion according to any one of claims 11-14, wherein the solubilizer is present in an amount of approximately 8% to approximately 12% w / w.

16. The emulsion according to any one of claims 11-15, wherein the multikinase inhibitor is present in an amount of approximately 0.2% w / w.

17. The emulsion according to any one of claims 11-16, wherein the polyoxyl oil is present in an amount of approximately 0.5% w / w.

18. The emulsion according to any one of claims 11-17, wherein the lipophilic vehicle is present in an amount of approximately 0.25% w / w.

19. The emulsion according to any one of claims 11-18, in nezznn / Lznz / E / YiAi 66 wherein the solubilizer is present in an amount of approximately 10% w / w.

20. The emulsion according to any one of claims 11-19, wherein the multikinase inhibitor is selected from the group consisting of afatinib, amuvatinib, axitinib, cabozantinib, canertinib, cediranib, ceritinib, crenolanib, crizotinib, dabrafenib, dacomitinib, dasatinib, erlotinib, foretinib, gefitinib, golvatinib, ibrutinib, icotinib, idelalisib, imatinib, lapatinib, lenvatinib, neratinib, nilotinib, nintedanib, palbociclib, pazopanib, ponatinib, quizartinib, regorafenib, ruxolitinib, sorafenib, sunitinib, tandutinib, tivantinib, tivozanib, trametinib, vandetanib, vatalanib, vemurafenib or combinations of the same.

21. The emulsion according to any one of claims 11-20, wherein the multikinase inhibitor is selected from axitinib, nintedanib, and pazopanib.

22. The emulsion according to any one of claims 11-21, wherein the solubilizer is a cyclic polysaccharide.

23. The emulsion according to claim 22, wherein the cyclic polysaccharide is selected from the group consisting of cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, 2-hydroxypropyl-alpha-cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin, sulfobutyl ether-beta-cyclodextrin and combinations thereof.

24. The emulsion according to any one of claims 11-23, wherein the solubilizer comprises 2-hydroxypropyl-beta-cyclodextrin.

25. An emulsion comprising: approximately 0.2% w / w of a multikinase inhibitor selected from the group consisting of nintedanib, axitinib and pazopanib; approximately 0.5% w / w of a polyoxyl castor oil; approximately 0.25% w / w of castor oil; approximately 10% w / w of 2-hydroxypropyl-beta-cyclodextrin; and water.

26. The emulsion according to any one of claims 1-25 for use in the treatment of an eye condition.